1
|
Mehta H, Gabrielle PH, Hashimoto Y, Kibret GD, Arnold J, Guillaumie T, Kheir WJ, Kok G, Vujosevic S, O'Toole L, Mangelschots E, Jaross N, Ceklic L, Daien V, Viola F, Squirrell D, Lavid FJ, Creuzot-Garcher C, Barthelmes D, Gillies M. One-year anti-VEGF therapy outcomes in diabetic macular edema based on treatment intensity: Data from the FRB! registry. Ophthalmol Retina 2024:S2468-6530(24)00182-9. [PMID: 38615818 DOI: 10.1016/j.oret.2024.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 03/29/2024] [Accepted: 04/08/2024] [Indexed: 04/16/2024]
Abstract
PURPOSE To compare one-year outcomes of eyes with diabetic macular edema (DME) treated in routine clinical practice based on the proportion of visits where intravitreal vascular endothelial growth factor (VEGF) inhibitor injections were delivered. DESIGN Cohort study PARTICIPANTS: There were 2288 treatment-naïve eyes with DME starting intravitreal VEGF inhibitor therapy from 31 October 2015 to 31 October 2021 from the Fight Retinal Blindness! international outcomes registry. METHODS Eyes were grouped according to the proportion of visits at which an injection was received, Group A with less than the median of 67% (n=1172) versus Group B with greater than the median (n=1116). MAIN OUTCOME MEASURE Mean visual acuity (VA) change after 12 months of treatment. RESULTS The mean (95% confidence interval [CI]) VA change after 12 months of treatment was 3.6 (2.8, 4.4) letters for eyes in Group A versus 5.2 (4.4, 5.9) letters for eyes in Group B (p=0.005). The mean (95% CI) central subfield thickness (CST) change was -69 (-76, -61) μm and -85 (-92, -78) μm for eyes in Group A versus Group B, respectively (p=0.002). A moderate positive correlation was observed between the number of injections received over 12 months of treatment and the change in VA (p<0.001). Additionally, eyes that received more injections had a moderately greater CST reduction. CONCLUSIONS This registry analysis found that overall VA and anatomic outcomes tended to be better in DME eyes treated at a greater proportion of visits in the first year of intravitreal VEGF inhibitor therapy.
Collapse
Affiliation(s)
- Hemal Mehta
- The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, New South Wales, Australia; Department of Ophthalmology, Royal Free London NHS Foundation Trust, London, United Kingdom
| | - Pierre-Henry Gabrielle
- The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, New South Wales, Australia; Department of Ophthalmology, Dijon University Hospital, Dijon, France Eye Clinic.
| | - Yohei Hashimoto
- The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, New South Wales, Australia
| | - Getiye Dejenu Kibret
- The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, New South Wales, Australia
| | | | - Tremeur Guillaumie
- Department of Ophthalmology, Saint Brieuc Hospital, 22000 Saint Brieuc, France
| | - Wajiha Jurdi Kheir
- Department of Ophthalmology, American University of Beirut Medical Center, Beirut, Lebanon
| | - Gerhard Kok
- Dr. Gerhard Kok Inc. (private ophthalmology practice), Pretoria, South Africa
| | - Stela Vujosevic
- Department of Biomedical, Surgical and Dental Sciences University of Milan, Milan, Italy; Eye Clinic IRCCS MultiMedica, Milan, Italy
| | - Louise O'Toole
- Mater Private Network, Dublin & University College Dublin, Ireland
| | | | - Nandor Jaross
- Australian Eye Specialists (Wyndham), Werribee, Victoria, Australia
| | - Lala Ceklic
- University of Vitez, Travnik, Bosnia and Herzegovina
| | - Vincent Daien
- The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, New South Wales, Australia; Department of Ophthalmology, Gui de Chauliac Hospital, 80 Avenue Augustin Fliche, 34000, Montpellier, France
| | - Francesco Viola
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| | | | | | | | - Daniel Barthelmes
- The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, New South Wales, Australia; Department of Ophthalmology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
| | - Mark Gillies
- The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, New South Wales, Australia
| |
Collapse
|
2
|
Arnold J, Vijayakumar N, Levy P. Advanced imaging and modeling in neonatal simulation. Semin Perinatol 2023; 47:151825. [PMID: 37940437 DOI: 10.1016/j.semperi.2023.151825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2023]
Abstract
Advances in modeling and imaging have resulted in realistic tools that can be applied to education and training, and even direct patient care. These include point-of-care ultrasound (POCUS), 3-dimensional and digital anatomic modeling, and extended reality. These technologies have been used for the preparation of complex patient care through simulation-based clinical rehearsals, direct patient care such as the creation of patient devices and implants, and for simulation-based education and training for health professionals, patients and families. In this section, we discuss these emerging technologies and describe how they can be utilized to improve patient care.
Collapse
|
3
|
Lean I, Arnold J, Duddy C, Church S, Rose R, Hodgson D. Kristin Arnold 1956-2023. Aust Vet J 2023; 101:462. [PMID: 37918953 DOI: 10.1111/avj.13286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/09/2023] [Indexed: 11/04/2023]
|
4
|
Mitchell P, Arnold J, Fraser-Bell S, Kang HK, Chang AA, Tainton J, Simonyi S. Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study. BMJ Open Ophthalmol 2023; 8:e001224. [PMID: 37541745 PMCID: PMC10407411 DOI: 10.1136/bmjophth-2022-001224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Accepted: 04/26/2023] [Indexed: 08/06/2023] Open
Abstract
AIM To evaluate effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX) monotherapy in the AUSSIEDEX study non-responder subgroup, defined by diabetic macular oedema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. METHODS This prospective, open-label, observational, real-world study included pseudophakic and phakic (scheduled for cataract surgery) eyes that did not achieve a ≥5-letter best corrected visual acuity (BCVA) gain and/or clinically significant central subfield retinal thickness (CRT) improvement after 3-6 anti-VEGF injections for DME (N=143 eyes), regardless of baseline BCVA and CRT. After an initial DEX injection (baseline visit), reinjection was permitted at ≥16-week intervals. PRIMARY ENDPOINTS changes in mean BCVA and CRT from baseline to week 52. Safety assessments included adverse events. RESULTS Of 143 eyes, 53 (37.1%) and 89 (62.2%) switched to DEX after 3-6 (early) and >6 (late) anti-VEGF injections, respectively; 1 (0.7%) had missing information. With 2.3 injections (mean) over 52 weeks, the change in mean BCVA from a baseline of 57.8 letters was not significant at week 52. Mean CRT improved significantly from a baseline of 417.8 μm at week 52 (mean change -60.9 μm; p<0.001). Outcomes were similar in eyes switched to DEX early and late. No unexpected adverse events were reported; no filtration surgeries were required. CONCLUSION To date, AUSSIEDEX is the largest prospective, real-world study of DEX monotherapy for treatment-naïve or anti-VEGF-refractory DME. Following early or late switch from anti-VEGF agents, DEX significantly improved anatomic outcomes at 52 weeks without new safety concerns, supporting use in anti-VEGF-refractory DME. TRIAL REGISTRATION NUMBER NCT02731911.
Collapse
Affiliation(s)
- Paul Mitchell
- Westmead Institute for Medical Research / Sydney West Retina, University of Sydney, Sydney, New South Wales, Australia
| | | | - Samantha Fraser-Bell
- The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia
- Sydney Hospital and Sydney Eye Hospital, Sydney, New South Wales, Australia
| | - Hyong Kwon Kang
- Retina & Vitreous Centre, Sydney, New South Wales, Australia
| | - Andrew A Chang
- Sydney Retina Clinic & Day Surgery, Sydney, New South Wales, Australia
| | - Jodi Tainton
- Allergan, an AbbVie Company, Gordon, New South Wales, Australia
| | | |
Collapse
|
5
|
Arnold J. Improving a prostate cancer pathway with a nurse-led clinic. Br J Nurs 2023; 32:S4-S5. [PMID: 37173083 DOI: 10.12968/bjon.2023.32.9.s4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Jennifer Arnold, Prostate Cancer Nurse, Luton and Dunstable Hospital (jennifer.arnold2@nhs.net), runner-up in the Urology Nurse of the Year category of the BJN Awards 2023.
Collapse
|
6
|
Charles A, Williams SA, Dolan J, Rehman M, Arnold J, Chandler NM. Pediatric intraoperative cardiopulmonary arrests: A survey to evaluate if Medical Emergency Teams are utilized in pediatric operating rooms. Paediatr Anaesth 2023; 33:454-459. [PMID: 36932923 DOI: 10.1111/pan.14665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Revised: 03/03/2023] [Accepted: 03/13/2023] [Indexed: 03/19/2023]
Abstract
BACKGROUND Studies have shown that standardized code teams may improve outcomes following cardiac arrests. Pediatric intra-operative cardiac arrests are rare events and are associated with a mortality rate of 18%. There is limited data available regarding use Medical Emergency Team (MET) response to pediatric intra-operative cardiac arrest. The purpose of this study was to identify the use of MET in response to pediatric intraoperative cardiac arrest as an exploratory step in establishing evidence-based standardized practice across the hospital for training and management of this rare event. METHODS An anonymous electronic survey was created and sent to two populations: The Pediatric Anesthesia Leadership Council, a section of the Society for Pediatric Anesthesia, and the Pediatric Resuscitation Quality Collaborative, a multinational collaborative group, which works to improve resuscitation care in children. Standard summary and descriptive statistics were used for survey responses. RESULTS The overall response rate was 41%. The majority of respondents worked in a university affiliated, free-standing children's hospital. Ninety-five percent of respondents had a dedicated pediatric MET at their hospital. In 60% of responses from Pediatric Resuscitation Quality Collaborative and 18% of Pediatric Anesthesia Leadership Council hospitals, the MET responds to pediatric intra-operative cardiac arrest; however, the majority of times MET involvement is requested rather than automatic. The MET was found to be activated intraoperatively for situations other than cardiac arrest such as, massive transfusion events, need for extra staff, and for specialty expertise. In 65% of institutions, simulation-based training for cardiac arrest is supported but lacking pediatric intra-operative focus. CONCLUSIONS This survey revealed heterogeneity in the composition and response of the medical response teams responding to pediatric intra-operative cardiac arrests. Improved collaboration and cross training among MET, anesthesia, and operating room nursing may improve outcomes of pediatric intra-operative code events.
Collapse
Affiliation(s)
- Aidan Charles
- Division of Pediatric Surgery, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA
- University of Central Florida College of Medicine/Hospital Corporation of America, Graduate Medical Education Consortium, Ocala, Florida, USA
| | - Sacha A Williams
- Division of Pediatric Surgery, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA
| | - Jenny Dolan
- Department of Anesthesia, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA
| | - Mohamed Rehman
- Department of Anesthesia, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA
| | - Jennifer Arnold
- Center for Medical Simulation and Innovative Education, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA
| | - Nicole M Chandler
- Division of Pediatric Surgery, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA
| |
Collapse
|
7
|
Yuen YS, Gilhotra JS, Dalton M, Aujla JS, Mehta H, Wickremasinghe S, Uppal G, Arnold J, Chen F, Chang A, Fraser-Bell S, Lim L, Shah J, Bowditch E, Broadhead GK. Diabetic Macular Oedema Guidelines: An Australian Perspective. J Ophthalmol 2023; 2023:6329819. [PMID: 36824442 PMCID: PMC9943607 DOI: 10.1155/2023/6329819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 12/21/2022] [Accepted: 12/30/2022] [Indexed: 02/16/2023] Open
Abstract
The number of people living with diabetes is expected to rise to 578 million by 2030 and to 700 million by 2045, exacting a severe socioeconomic burden on healthcare systems around the globe. This is also reflected in the increasing numbers of people with ocular complications of diabetes (namely, diabetic macular oedema (DMO) and diabetic retinopathy (DR)). In one study examining the global prevalence of DR, 35% of people with diabetes had some form of DR, 7% had PDR, 7% had DMO, and 10% were affected by these vision-threatening stages. In many regions of the world (Australia included), DR is one of the top three leading causes of vision loss amongst working age adults (20-74 years). In the management of DMO, the landmark ETDRS study demonstrated that moderate visual loss, defined as doubling of the visual angle, can be reduced by 50% or more by focal/grid laser photocoagulation. However, over the last 20 years, antivascular endothelial growth factor (VEGF) and corticosteroid therapies have emerged as alternative options for the management of DMO and provided patients with choices that have higher chances of improving vision than laser alone. In Australia, since the 2008 NHMRC guidelines, there have been significant developments in both the treatment options and treatment schedules for DMO. This working group was therefore assembled to review and address the current management options available in Australia.
Collapse
Affiliation(s)
| | | | | | - Jaskirat S. Aujla
- South Australian Institute of Ophthalmology, Adelaide, SA, Australia
| | - Hemal Mehta
- Save Sight Registries, University of Sydney, Sydney, NSW, Australia
- Strathfield Retina Clinic, Sydney, Australia
| | - Sanj Wickremasinghe
- Centre for Eye Research Australia, The Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia
| | - Gurmit Uppal
- Moreton Eye Group, Brisbane, Queensland, Australia
| | | | - Fred Chen
- Centre for Ophthalmology and Visual Sciences (Incorporating Lions Eye Institute), The University of Western Australia, Nedlands, WA, Australia
- Ophthalmology, Department of Surgery, University of Melbourne, Victoria, Australia
| | - Andrew Chang
- Sydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia
- Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia
- Save Sight Institute, University of Sydney, Sydney, NSW, Australia
| | - Samantha Fraser-Bell
- Department of Ophthalmology, Save Sight Institute, University of Sydney, Sydney, NSW, Australia
| | - Lyndell Lim
- Centre for Eye Research Australia, The Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia
| | - Janika Shah
- Sydney Eye Hospital, Sydney, Australia
- Singapore National Eye Centre, Singapore
| | - Ellie Bowditch
- Save Sight Institute, University of Sydney, Sydney, NSW, Australia
| | | |
Collapse
|
8
|
Hunt A, Nguyen V, Bhandari S, Ponsioen T, McAllister IL, Arnold J, Young S, Gabrielle PH, Mehta H, O' Toole L, Alforja S, Zarranz-Ventura J, Barthelmes D, Gillies M. Central retinal vein occlusion 36-month outcomes with anti-vascular endothelial growth factors: the Fight Retinal Blindness! registry. Ophthalmol Retina 2022; 7:338-345. [PMID: 36371040 DOI: 10.1016/j.oret.2022.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Revised: 10/26/2022] [Accepted: 11/03/2022] [Indexed: 11/11/2022]
Abstract
PURPOSE To analyze the 3-year outcomes in a broad population of patients starting VEGF inhibitors for central retinal vein occlusion (CRVO) in routine clinical practice. DESIGN Observational database study. PARTICIPANTS Overall, 527 treatment-naïve CRVO eyes that commenced VEGF inhibitors between December 1, 2010 and 2018 were tracked in the Fight Retinal Blindness! registry. METHODS Longitudinal models were used to plot changes in visual acuity (VA) and central subfield thickness (CST). MAIN OUTCOME MEASURES Mean change in VA from baseline to 36 months, injections, visits, completion, switching, and suspensions of therapy > 180 days at the final review. RESULTS Overall (527 eyes) mean VA change (95% confidence interval [CI]) was + 10 (7, 12) letters, 37% had final VA ≥ 70 and 30% ≤ 35 letters, mean CST changed -306 μm. Completers (257/527, 49%) had mean 36-month changes in VA and CST of + 12 letters and -324 μm with a median of 18 injections at 26 visits. The adjusted mean VA change was similar to each VEGF inhibitor (mean, + 11.4 letters) despite a greater reduction in CST with aflibercept (-310 μm) versus ranibizumab (-258 μm) versus bevacizumab (-216 μm; P < 0.001). Eyes with baseline VA that was trial-eligible (19-73 letters; 356/527, 68%) gained 7 letters, very poor (< 19 letters; 129/527, 24%) gained 22 letters, or very good (> 73 letters; 42/527, 8%) lost 7 letters. Switching (160/527, 30%) was most often to aflibercept (79 eyes). By using suspensions and discontinuation reasons, we identified similar proportions had ceased therapy (154/527, 29%) and were still receiving it at 36 months (165/527, 31%). Only 62/527 eyes (12%) had resolution of macular edema without treatment for > 6 months. CONCLUSIONS Patients with CRVO that commenced VEGF inhibitors in routine care for whom follow-up was available had VA improvements of around 12 letters at 3 years, but with > 50% lost to follow-up, the VA outcome for the entire group was likely worse. The choice of VEGF inhibitor influenced CST but not VA outcomes. We estimated that around half of the eyes were still receiving injections after 36 months. FINANCIAL DISCLOSURE(S) Proprietary or commercial disclosure may be found after the references.
Collapse
Affiliation(s)
- Adrian Hunt
- The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Ophthalmology, Westmead Hospital, New South Wales, Australia.
| | - Vuong Nguyen
- The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Sanjeeb Bhandari
- The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; National Eye Institute, Bethesda, Maryland
| | | | - Ian L McAllister
- Centre for Ophthalmology and Visual Science, Lions Eye Institute, The University of Western Australia, Perth, Western Australia, Australia
| | - Jennifer Arnold
- Marsden Eye Specialists, Parramatta, New South Wales, Australia
| | - Stephanie Young
- Gladesville Eye Specialists, Gladesville, New South Wales, Australia
| | - Pierre-Henry Gabrielle
- The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Ophthalmology, Dijon University Hospital, Dijon, France
| | - Hemal Mehta
- The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Ophthalmology Department, Royal Free London NHS Foundation Trust, London, United Kingdom
| | | | - Socorro Alforja
- Institute Clínic of Ophthalmology (ICOF), Hospital Clinic, Barcelona, Spain
| | | | - Daniel Barthelmes
- The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Ophthalmology, University Hospital and University of Zurich, Zurich, Switzerland
| | - Mark Gillies
- The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
9
|
Zahler D, Arnold J, Rozenbaum Z, Banai S, Arbel Y, Topilsky Y, Laufer-Perl M. Valvular changes following anthracycline therapy: is it time to look beyond ejection fraction? Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Advancements in early detection and treatment of breast cancer have improved survival, but with the costs of side effects, with cardiotoxicity being the most significant one. Anthracycline (ANT) is the most recognized therapy leading to cardiotoxicity, mainly manifested as left ventricle (LV) dysfunction. While the changes in LV ejection fraction (LVEF) are well studied, little is known about the effect of ANT on valvular function. We aimed to evaluate the change in valvular function following ANT therapy in patients diagnosed with breast cancer.
Methods
The study population is part of the Israel Cardio-Oncology Registry (ICOR). All patients performed serial echocardiography; before (T1), during (T2), at the end (T3), and following (T4) ANT therapy, assessing valvular changes. Exclusion criteria included age below 18 and baseline LVEF <55%.
Results
The study included 141 female patients diagnosed with breast cancer and treated with ANT with a mean age of 51±12 years (Table 1). During a median follow-up of 255 [IQR 214–313] days, from T1 to T4, we observed a significant increase in the portion of patients developing new mitral regurgitation (MR) (3.5% to 18.7%, p<0.0001), with a trend for developing moderate and above MR (0.7% to 3.3%, p=0.13). While a statistically significant reduction in mean LVEF (60.2%±1.5 to 59.2%±2.7, p=0.0004) and median LV global longitudinal strain (LV GLS) (−21.6% [−20.0 to −23.0] to −20.0% [−19.1 to −21.1], p<0.0001) was observed (Figure 1), the values remain within the normal range with no significant clinical change. In a multivariate binary logistic regression model, age (OR 1.06, 95% CI: 1.01–1.11) and trastuzumab therapy (OR 5.59, 95% CI: 1.95–16.6) were strong independent predictors for MR development, while medical history was not.
Conclusions
MR development following ANT exposure is frequent, increasingly after the completion of ANT therapy. The parallel reduction in LV function might imply a functional mechanism. Larger trials are needed to evaluate the MR prognostic clinical role in cancer patients.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- D Zahler
- Tel Aviv Sourasky Medical Center, Cardiology , Tel Aviv , Israel
| | - J Arnold
- University of Illinois at Chicago, Department of Medicine , Chicago , United States of America
| | - Z Rozenbaum
- Tel Aviv Sourasky Medical Center, Cardiology , Tel Aviv , Israel
| | - S Banai
- Tel Aviv Sourasky Medical Center, Cardiology , Tel Aviv , Israel
| | - Y Arbel
- Tel Aviv Sourasky Medical Center, Cardiology , Tel Aviv , Israel
| | - Y Topilsky
- Tel Aviv Sourasky Medical Center, Cardiology , Tel Aviv , Israel
| | - M Laufer-Perl
- Tel Aviv Sourasky Medical Center, Cardiology , Tel Aviv , Israel
| |
Collapse
|
10
|
Shaffi M, Saad N, Arnold J, Parker G, Nguyen D, Eftekhar B. An Ocular Chameleon. Neurohospitalist 2022; 12:672-675. [PMID: 36147764 PMCID: PMC9485686 DOI: 10.1177/19418744221111251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023] Open
Abstract
Patients presenting with transient visual loss is common in emergency departments. Neurologists, ophthalmologists and emergency care physicians may be called upon to evaluate such patients. Monocular visual loss should be differentiated from the binocular involvement as the oetologies, investigations and management of such patients differ considerably. We report a case of monocular visual loss that involved predominantly one eye but affected the other side independently, albeit less frequently. A meticulous history, thorough general, neurological and ophthalmological examinations are necessary in such patients to identify the cause and to treat appropriately. Ocular ischemic syndrome (OIS) is due to chronic hypoperfusion of the structures supplied by ophthalmic artery leading to monocular visual loss. Stenosis of the ipsilateral internal carotid artery from a variety of causes is the main underlying mechanism. The first case of OIS was reported by Hedges in 1963 and the term was coined later by Barry and Magargal. Ocular ischemic syndrome is an important differential diagnosis to consider especially in older people and those with vascular risk factors. An overview of important differential diagnosis, clinical features and treatment of OIC are discussed in this article. A multidisciplinary team is optimal for the management of ocular ischemic syndrome.
Collapse
Affiliation(s)
- Mohamed Shaffi
- Department of Medicine, University of Notre Dame, Sydney, NSW, Australia
| | - Nick Saad
- Department of Ophthalmology, Marsden Eye Specialists, Parramatta, NSW, Australia
| | - Jennifer Arnold
- Department of Ophthalmology, Marsden Eye Specialists, Parramatta, NSW, Australia
| | - Geoffrey Parker
- Department of Radiology, Macquarie University Hospital, North Ryde, NSW, Australia
| | - Daniel Nguyen
- Department of Surgery, Macquarie University Hospital, North Ryde, NSW, Australia
| | - Behzad Eftekhar
- Department of Neurosurgery, The University of Sydney, Sydney, NSW, Australia
| |
Collapse
|
11
|
Sadda SR, Holz FG, Staurenghi G, Invernizzi A, Arnold J, Tadayoni R. The Importance of Imaging to Identify Early Signs of Intraocular Inflammation Expert Opinion for Brolucizumab. Ophthalmologica 2022; 245:588-591. [PMID: 36130526 DOI: 10.1159/000526703] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Accepted: 05/18/2022] [Indexed: 02/02/2023]
Affiliation(s)
- SriniVas R Sadda
- Doheny Eye Institute, University of California, Los Angeles, California, USA
| | - Frank G Holz
- Department of Ophthalmology, University of Bonn, Bonn, Germany
| | - Giovanni Staurenghi
- Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, Milan, Italy
| | - Alessandro Invernizzi
- Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, Milan, Italy.,Save Sight Institute, The University of Sydney, Sydney, New South Wales, Australia
| | | | - Ramin Tadayoni
- Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Hôpital Fondation Adolphe de Rothschild, Université de Paris, Paris, France
| |
Collapse
|
12
|
Md. Yusof MY, Arnold J, Saleem B, Vandevelde C, Dass S, Savic S, Vital E, Emery P. OP0250 BREAKTHROUGH INFECTIONS AND PREDICTING SEVERE COVID OUTCOMES DURING RITUXIMAB THERAPY IN AUTOIMMUNE RHEUMATIC DISEASES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundAs rituximab (RTX) is a B-cell depleting agent, there are concerns regarding its safety during the COVID pandemic. Data from registries during pre-vaccination period reported increased risk of poor outcomes in RTX-treated patients vs TNFi. However, registry data could be limited by reporting bias in determining true incidence. There are also limited data on breakthrough infections following COVID vaccination.ObjectivesTo assess the incidence of breakthrough infections and predictors of severe COVID outcomes in RTX-treated autoimmune rheumatic diseases (ARDs) with a view to establishing a treatment algorithm for safe RTX administration.MethodsAn observational cohort study was undertaken in the first consecutive 300 ARD patients in a single centre between index date 01/09/2019 (i.e. 6 months prior to pandemic) and 31/01/2022. Only PCR positive cases were included. COVID outcomes were categorised as Mild (i.e. not hospitalised) or Moderate/Severe (i.e. hospitalised and requiring at least oxygenation or death). Predictors of moderate/severe outcomes were analysed using Cox-regression proportional hazard.ResultsMean (SD) at index date was 59 (14) years, 226/300 (75%) patients were female and 254 (85%) were Caucasians. The diagnoses were RA=212 (71%), SLE=33 (11%), AAV=26 (9%), Sjogren=9 (3%), IIM=8 (3%) and others=12 (4%). Therapy included concomitant DMARDs = 205 (68%) and oral prednisolone = 84 (28%). Median (range) no. of previous RTX courses was 4 (0-19). 534 RTX courses were administered. Of 294 patients with available vaccine data, 17 (6%) were unvaccinated, 4 (1%) had a single dose, 47 (16%) were double-vaccinated, 217 (74%) triple-vaccinated and 9 (3%) quadruple-vaccinated. Of those who were vaccinated, for the first dose, 11% were given within 12 weeks post-RTX, 15% within 26 weeks and 74% were >26 weeks post-RTX. The rate of overall COVID and moderate/severe infections were 11.2/100 PYs and 2.6/100 PYs respectively. Vaccinated patients had lower rate of moderate/severe infection (2.6/100 PYs) vs unvaccinated (18.6/100 PYs) [Table 1]. Over 650.7 PY follow-up, 17/300 patients (5.7%) had moderate/severe COVID including 2 deaths. Factors associated with time-to-infection in imputed multivariable analysis were number of comorbidities [HR 1.46 (95% CI 1.05-2.04)] and low IgG (<6g/L) [6.15 (1.95-19.41)]. A history of COVID vaccination reduced risk [HR 0.13 (0.03-0.51)]. Demographics including concomitant prednisolone, RTX- and vaccine-associated factors (e.g. RTX dose, time from RTX to vaccine, vaccine mode, peripheral B-cell depletion) were not predictive.Table 1.Incidence of COVID infectionPre-Vaccination ProgrammePost-Vaccination ProgrammeOverall Follow-upOverall COVID rate3.3/100 PYNon-vaccinated = 37.7/100 PY73 cases in 650.7 years] = 11.2/100 PYVaccinated = 18.6/100 PYModerate/Severe COVID rate2.1/100 PYNon-Vaccinated = 15.1/100 PY17 cases in 650.7 years] = 2.6/100 PYVaccinated = 2.6/100 PYConclusionThe rate of moderate/severe COVID infection in this cohort is comparable to the pre-pandemic severe infection rate in rituximab trials in RA. The high vaccination uptake in our cohort was effective in preventing severe infection despite the termination of national shielding programme in March 2021 and the spread of the Delta and Omicron variants. Individualised risk–benefit assessment should be undertaken in those with comorbidities, low IgG and unvaccinated when scheduling rituximab therapy.ReferencesNoneAcknowledgementsThis research was funded/supported by the the Wellcome Trust Institutional Strategic Support Fund to MYMY (204825/Z/16/Z), National Institute for Health Research (NIHR) Doctoral Research Fellowship to MYMY (DRF-2014-07-155) and NIHR Clinician Scientist to EMV (CS-2013-13-032). PE is a Versus Arthritis Professor of Rheumatology. This article/paper/report also presents independent research funded/supported by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.Disclosure of InterestsMd Yuzaiful Md Yusof Consultant of: Aurinia Pharmaceuticals, Jack Arnold: None declared, Benazir Saleem: None declared, Claire Vandevelde: None declared, Shouvik Dass: None declared, Sinisa Savic Speakers bureau: Novartis, Swedish Orphan Biovitrum (SOBI) and Sire, Grant/research support from: Novartis, Swedish Orphan Biovitrum, Octapharma and CSL Behring, Edward Vital Speakers bureau: Roche, GSK and AstraZeneca, Grant/research support from: Roche, GSK and AstraZeneca, Paul Emery Consultant of: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, Grant/research support from: Abbott, BMS, Pfizer, MSD and Roche.
Collapse
|
13
|
Arnold J, Dass S, Twigg S, Jones C, Rhodes B, Hewins P, Chakravorty M, Courtney P, Ehrenstein M, Md. Yusof MY, Vital E. AB0434 EFFICACY AND SAFETY OF OBINUTUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH SECONDARY NON-RESPONSE TO RITUXIMAB. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundSecondary inefficacy characterized by infusion reactions and anti-drug antibodies occur in 14% of SLE patients treated with repeat rituximab courses(1). Obinutuzumab is a next-generation humanized type-2 anti-CD20 therapy licensed for hematological malignancies which may overcome this issue(2).ObjectivesWe set out to evaluate the clinical efficacy and safety of obinutuzumab in a cohort of rituximab resistant SLE patients.MethodsWe collated data from SLE patients receiving obinutuzumab for secondary non-response to rituximab in BILAG centres. Disease activity was assessed using BILAG-2004, SLEDAI-2K and serology before, and 6 months after, obinutuzumab 2x1000mg infusions alongside methylprednisolone 100mg. Flow cytometry where possible was carried out using a multiple gating highly sensitive strategy.ResultsAll 9 patients included in the study received obinutuzumab alongside concomitant oral immunosuppression. At 6 months post-obinutuzumab, there were significant reductions in median SLEDAI-2K from 12 to 6 (p=0.014) and total BILAG-2004 score from 21 to 2 (p=0.009). Complement C3 and dsDNA titres improved significantly (both p=0.04). Non statistically significant numerical improvements were seen in C4 levels.Of 8/9 patients receiving concomitant oral prednisolone at baseline (all >10mg/day), 5/9 had their dose reduced at 6 months; 4/8 were on 5mg/day and were in Lupus Low Disease Activity State. After obinutuzumab, 6/9 patients with peripheral B-cell data achieved complete depletion including 4/4 assessed with highly sensitive assays. 1/9 obinutuzumab non-responder required cyclophosphamide therapy. 1 unvaccinated patient died from COVID-19.Table 1.Baseline characteristics, disease activity and steroid doses before and after last obinutuzumab/rituximab.PatientEthnicityDisease duration (Years)Age (Years)Total BILAG-2004 before ObiTotal BILAG-2004 after ObiSLEDAI-2K before ObiSLEDAI-2K after ObiPrednisolone before Obi (mg)Prednisolone after Obi (mg)1South Asian10.836.41821481052South Asian6.324.424212430103South Asian11.934.829110410104South Asian8.241.92116015155South Asian6.829.43221181450606White European17.537.0128881557White European16.930.01211281058Caribbean6.244.225213010159Caribbean2.621.092166105Median (Q1, Q3)NA8.2 (6, 12)34.8 (29,37)21 (12, 25)2 (1, 2)12 (10, 14)6 (4, 8)10 (10, 15)10 (5, 15)ConclusionObinutuzumab appears to be effective and steroid-sparing in renal and non-renal SLE patients with secondary non-response to rituximab. Obinutuzumab was shown to be effective in patients with severe renal and non-renal disease. Therefore, in those with previous responsiveness to B-cell depletion, switching to humanised type-2 anti-CD20 therapy is a logical approach following loss off efficacy.References[1]Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum [Internet]. 2011 Oct [cited 2020 Oct 12];63(10):3038–47. Available from: https://pubmed.ncbi.nlm.nih.gov/21618204/[2]Hassan SU, Md Yusof MY, Emery P, Dass S, Vital EM. Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab. Front Med [Internet]. 2020 Aug 27 [cited 2020 Sep 2];7:498. Available from: https://www.frontiersin.org/article/10.3389/fmed.2020.00498/fullDisclosure of InterestsJack Arnold: None declared, Shouvik Dass Consultant of: Roche, Abbvie, UCB & Chugai, Employee of: Honoraria from Roche, Abbvie, UCB & Chugai, Sarah Twigg: None declared, Colin Jones: None declared, Benjamin Rhodes: None declared, Peter Hewins: None declared, Mithun Chakravorty: None declared, Philip Courtney: None declared, Michael Ehrenstein Grant/research support from: GSK, Employee of: Has received honoraria from GSK, Md Yuzaiful Md Yusof: None declared, Edward Vital Employee of: Has received honoraria from Roche
Collapse
|
14
|
Arnold J, Carter LM, MD Yusof MY, Wigston Z, Hassan SU, Dutton K, Dass S, Psarras A, Vital E. AB0510 IMMUNOPHENOTYPIC RECLASSIFICATION OF ANA ASSOCIATED AUTOIMMUNE DISEASE: PRELIMINARY ANALYSIS OF FLOW CYTOMETRIC DATA IN A MULTI-DISEASE COHORT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe heterogeneity within the connective tissue disease patient cohort is not adequately reflected by current diagnostic labels(1,2). An immunophenotypic classification may be more appropriate for targeting therapy and basket therapeutic trials. DEFINITION is a multi-disease cohort (n=300) containing multiple clinical and immune datasets.ObjectivesTo perform preliminary clustering analysis using the flow cytometric dataset from DEFINITION.Methods142 patients with comprehensive flow cytometry data available were selected from the DEFINITION cohort. Highly sensitive flow cytometry was used to identify 7 B cell, T cell, NK cell and monocyte subsets and tetherin/SIGLEC1 expression on each subset.ANA and ENA titres were assessed via the Bioplex assay. Demographic and clinical data was obtained from the DEFINITION cohort. Multiple classification algorithms were applied to flow cytometry data using R. Including K-means, hierachical, model-based and partitioning around medioids (PAM). Output clusters were retrospectively compared to their legacy diagnoses and serology.ResultsIn the first 142 patients, PAM identified 3 clusters with memberships of 45, 49 and 48 patients respectively (Table 1).Table 1.Key legacy diagnoses and ENA positivity for the identified clusters.DiagnosisTotalCluster 1Cluster 2Cluster 3P valueSLE57221025>0.01UCTD2512850.06Sjogren’s152490.06Systemic sclerosis70520.07MCTD92430.76Myositis83320.86Antibody positivitydsDNA431611160.33Ro604512726>0.01Ro5236107190.01La182214>0.01Sm141490.02Sm_RNP2375110.23RNP143560.64SCL-7010010.37Jo-141210.80Centromere51400.08Chromatin29108110.68Ribosomal P41120.78Cluster 1 (UCTD/CD3+ dominant) was characterised by a higher proportion of UCTD patients (27%) and larger populations of CD3+ T cells and NK bright cells.Cluster 2 (SSc dominant/Tetherin low) was characterised by a higher population of systemic sclerosis (SSc) patients (10%) and a lower proportion of SLE patients (20%). High levels of classical and non-classical monocytes were demonstrated alongside low plasmablast populations and low SIGLEC1/Tetherin expression.Cluster 3 (SLE/pSS high, Ro/Tetherin high) included a higher proportion of SLE and primary Sjogren’s syndrome (pSS) patients (52% and 19%). This cluster showed larger plasmablast numbers and higher SIGLEC1/Tetherin expression. Serologically this cluster had higher levels of Ro60, Ro52, Sm-RNP and La positivity.There were statistically significant differences in Ro60, Ro52, La, and Sm antibody positivity between the 3 clusters. Significant differences in CD19+CD27+ memory B cell tetherin expression and CD14+CD16- classical monocyte SIGLEC1 expression were observed (both p < 0.05). A significant difference in SLE distribution was noted between the clusters (p < 0.01).ConclusionThis preliminary study identified of a flow cytometric dataset identified 3 immunophenotypically distinct subgroups, each comprised of multiple legacy diagnoses within spectrum of ANA+ disease. Future work will evaluate other datasets within the full cohort with a view to conduct basket trials in the baskets defined.References[1]Mucke J, Alarcon-Riquelme M, Andersen J, Aringer M, Bombardieri S, Brinks R, et al. What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. Lupus Sci Med [Internet]. 2021 May 20 [cited 2021 Jul 12];8(1):506. Available from: /pmc/articles/PMC8141446/[2]Barturen G, Beretta L, Cervera R, Van Vollenhoven R, Alarcón-Riquelme ME. Moving towards a molecular taxonomy of autoimmune rheumatic diseases [Internet]. Vol. 14, Nature Reviews Rheumatology. Nature Publishing Group; 2018 [cited 2021 Jun 28]. p. 75–93. Available from: https://pubmed.ncbi.nlm.nih.gov/29362467/AcknowledgementsFunding: AstraZenecaDisclosure of InterestsJack Arnold: None declared, Lucy Marie Carter: None declared, Md Yuzaiful Md Yusof: None declared, Zoe Wigston: None declared, Sabih-Ul Hassan: None declared, Katherine Dutton: None declared, Shouvik Dass Speakers bureau: Honoraria from Roche, Consultant of: Roche, Abbvie, UCB & Chugai, Antonios Psarras: None declared, Edward Vital Speakers bureau: GSK, AstraZeneca, Consultant of: AstraZeneca, Lilly, Roche, GSK, Aurinia, Iltoo, Novartis, Grant/research support from: Research grants paid to the employer: AstraZeneca and Sandoz
Collapse
|
15
|
Carter LM, Md Yusof MY, Plant D, Alase A, Arnold J, Psarras A, Wigston Z, Vital E. OP0234 RNA-Seq IN PERIPHERAL BLOOD IMMUNE CELLS IDENTIFIES MODULAR NETWORKS PREDICTIVE AND PROTECTIVE FOR PROGRESSION FROM ANA POSITIVITY TO CLASSIFIABLE SYSTEMIC AUTOIMMUNE DISEASE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundAnti-nuclear antibody (ANA) positivity represents a complex ‘At-Risk’ state for development of connective tissue disease (CTD). While ANA may become positive years in advance of clinically manifest CTD, they are also harboured in at least low titre by up to 25% of the wider population, of whom only a small fraction ultimately develop systemic autoimmunity. Complex immune disturbances including plasmacytoid dendritic cell exhaustion and non-haematopoietic interferon (IFN) production are evident even among ANA positive individuals who do not ultimately progress to overt disease [1].In a prospective observational cohort of ANA positive individuals At-Risk for CTD we have shown that a validated blood IFN-Score was predictive of progression to classifiable SLE [2]. However, the wider transcriptional fingerprint of the At-Risk state and other factors modifying risk of progression are not known. We hypothesise that diverse immune processes, both independent and interacting with IFN pathway activation, could modulate risk of progression.ObjectivesTo investigate how peripheral blood immune cell transcriptional signatures derived by RNA Seq associate with progression or non-progression from At-Risk ANA positivity to clinically apparent CTD.MethodsPeripheral blood mononuclear cells (PBMCs) were isolated at baseline from ANA-positive At-Risk individuals demonstrating ≤1 clinical criterion for classifiable CTD, symptom duration <12 months and naive of glucocorticoid or immunosuppressive therapy. Progression was prospectively adjudicated at 12 months and defined as accrual of clinical/ immunological criteria sufficient to meet classification for SLE (SLICC 2012) or other relevant CTDs. Bulk RNASeq was performed on PMBCs from 16 progressors and 19 non-progressors. Weighted gene co-expression network analysis (WGCNA) was performed using WGCNA package and gene ontology enrichment was evaluated using ClusterProfiler, in R Bioconductor. The top 20% genes ranked by connectivity were defined as hub genes. Major cell subsets were quantified in parallel by multiparameter flow cytometry.Results29 modules were identified by WGCNA. Eigengenes for 3 modules were significantly associated with progression status. A single, 152 gene module showed strong positive correlation with progression (R=0.55, p<0.001). Hub genes were significantly enriched for type I IFN-signalling pathway and included established interferon stimulated genes such as IFI44 and IRF7.Two further modules had a negative, i.e. protective, association with progression; a smaller 37 gene module, correlated negatively with both blood interferon score (R=-0.46, p=0.005) and with progression (R=-0.43, p=0.01). A larger 252 gene module was also negatively related to progression (R=-0.43, p=0.009) and demonstrated significant pathway enrichment for regulation of cell morphogenesis and actin cyctoskeleton organisation.ConclusionWe identify novel modular transcriptomic signatures implicated in SLE disease initiation. We show (i) IFN-pathway activation is the single strongest transcriptomic risk marker of progression from the ANA positive At Risk state and (ii) we identify 2 novel protective signatures in peripheral blood immune cells for which further network-based characterization is ongoing.References[1]Psarras et al. 2020 Nat Commun 11: 6149.[2]Md Yusof MY, et al. Ann Rheum Dis 2018;77:1432–1439.Disclosure of InterestsLucy Marie Carter: None declared, Md Yuzaiful Md Yusof Consultant of: Aurinia Pharmaceuticals, Darren Plant: None declared, Adewonuola Alase: None declared, Jack Arnold: None declared, Antonios Psarras: None declared, Zoe Wigston: None declared, Edward Vital Consultant of: AstraZeneca, Genentech, Aurinia, Lilly, ILTOO and Modus Therapeutics., Grant/research support from: Astra Zeneca and Sandoz
Collapse
|
16
|
Niedzwiecki M, Hunt A, Nguyen V, Mehta H, Creuzot‐Garcher C, Gabrielle P, Guillemin M, Fraser‐Bell S, Arnold J, McAllister IL, Gillies M, Barthelmes D. 12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry. Acta Ophthalmol 2022; 100:e920-e927. [PMID: 34519167 PMCID: PMC9292733 DOI: 10.1111/aos.15014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2021] [Accepted: 08/31/2021] [Indexed: 11/28/2022]
Abstract
Purpose To compare 12‐month treatment outcomes of eyes receiving aflibercept or ranibizumab for macular oedema secondary to central retinal vein occlusion (CRVO) in routine clinical practice. Methods 296 treatment‐naïve eyes receiving either aflibercept (171 eyes, 2 mg) or ranibizumab (125 eyes, 0.5 mg) for macular oedema secondary to CRVO were recruited retrospectively from centres using the prospectively designed FRB! registry. The primary outcome measure was the mean change in LogMAR letter scores of visual acuity (VA). Secondary outcomes included change in central subfield thickness (CST), injections and visits, time to first grading of inactivity, switching and non‐completion from baseline to 12 months. Results Baseline VA (SD) was somewhat better in aflibercept‐ versus ranibizumab‐treated eyes (42.5 ± 25.5 letters versus 36.9 ± 26 letters; p = 0.07) with similar CST (614 (240) μm versus 616 (234) μm: p = 0.95). The 12‐month adjusted mean (95%CI) VA change was +16.6 (12.9, 20.4) letters for aflibercept versus +9.8 (5.5, 14.1) letters for ranibizumab (p = 0.001). The mean (95%CI) adjusted change in CST was significantly greater in aflibercept‐ versus ranibizumab‐treated eyes: −304 (−276, −333) µm versus −252 (−220, −282) µm (p < 0.001). Both groups had a median (Q1, Q3) of 7 (5, 9) injections and 10 (8,13) visits. Aflibercept‐treated eyes became inactive sooner than ranibizumab (p = 0.02). Switching occurred more commonly from ranibizumab (26 eyes, 21%) than from aflibercept (9 eyes, 5%) (p < 0.001). Conclusion Both aflibercept and ranibizumab improved VA and reduced CST in eyes with CRVO in routine clinical practice, with aflibercept showing significantly greater improvements in this comparative analysis.
Collapse
Affiliation(s)
- Mateusz Niedzwiecki
- Department of Ophthalmology University Hospital Zurich & University of Zurich Zurich Switzerland
| | - Adrian Hunt
- Department of Ophthalmology Westmead Hospital Westmead NSW Australia
- The Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
| | - Vuong Nguyen
- The Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
| | - Hemal Mehta
- The Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
- Ophthalmology Department Royal Free London NHS Foundation Trust London UK
| | | | - Pierre‐Henry Gabrielle
- The Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
- Department of Ophthalmology Dijon University Hospital Dijon France
| | - Martin Guillemin
- Department of Ophthalmology Dijon University Hospital Dijon France
| | - Samantha Fraser‐Bell
- The Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
| | | | - Ian L. McAllister
- Centre for Ophthalmology and Visual Science Lions Eye Institute The University of Western Australia Perth WA Australia
| | - Mark Gillies
- The Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
| | - Daniel Barthelmes
- Department of Ophthalmology University Hospital Zurich & University of Zurich Zurich Switzerland
- The Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
| |
Collapse
|
17
|
Gabrielle P, Nguyen V, Bhandari S, Mehta H, Viola F, Arnold J, Fraser‐Bell S, Barthelmes D, Creuzot‐Garcher C, Gillies M. Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry. Acta Ophthalmol 2022; 100:285-294. [PMID: 33196150 PMCID: PMC9290829 DOI: 10.1111/aos.14672] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Revised: 10/08/2020] [Accepted: 10/11/2020] [Indexed: 01/18/2023]
Abstract
Purpose To compare visual acuity (VA) change at 24 months in eyes with clinically significant DME (CSDME) and good VA initially treated versus initially observed in routine clinical practice. Methods Retrospective analysis of treatment‐naïve eyes with CSDME and good VA (baseline VA ≥ 79 letters), with at least 24 months of follow‐up and initially managed with treatment (intravitreal treatment and/or macular laser) or observation with possible treatment after 4 months that were tracked in a prospectively designed observational registry. Results We identified 150 eligible eyes (98 initially observed, 52 initially treated) of 130 patients. The proportion of eyes with at least a 5‐letter VA loss at 24 months was not significantly different between the groups: 65% with initial observation and 42% with initial treatment (p = 0.39). However, initially observed eyes were more likely to have a 10‐letter VA loss at 24 months (OR = 4.6, p = 0.022). Most of eyes in the initial observation group received at least one treatment (an intravitreal injection in 66% and macular laser in 20%) during the 24‐month period. Conclusions The risk of 5 letters loss was similar between both management groups. However, initially observed eyes were more at risk of developing moderate visual loss and more than 80% of them required treatment over 24 months.
Collapse
Affiliation(s)
- Pierre‐Henry Gabrielle
- Sydney Medical School Discipline of Ophthalmology Save Sight Institute The University of Sydney Sydney New South Wales Australia
- Department of Ophthalmology Dijon University Hospital Dijon France
| | - Vuong Nguyen
- Sydney Medical School Discipline of Ophthalmology Save Sight Institute The University of Sydney Sydney New South Wales Australia
| | - Sanjeeb Bhandari
- Sydney Medical School Discipline of Ophthalmology Save Sight Institute The University of Sydney Sydney New South Wales Australia
| | - Hemal Mehta
- Sydney Medical School Discipline of Ophthalmology Save Sight Institute The University of Sydney Sydney New South Wales Australia
- Department of Ophthalmology Royal Free London NHS Foundation Trust London UK
| | - Francesco Viola
- IRCCS Cà Granda Foundation Maggiore Policlinico Hospital University of Milan Milan Italy
| | | | - Samantha Fraser‐Bell
- Sydney Medical School Discipline of Ophthalmology Save Sight Institute The University of Sydney Sydney New South Wales Australia
| | - Daniel Barthelmes
- Sydney Medical School Discipline of Ophthalmology Save Sight Institute The University of Sydney Sydney New South Wales Australia
- Department of Ophthalmology University Hospital Zurich University of Zurich Zurich Switzerland
| | | | - Mark Gillies
- Sydney Medical School Discipline of Ophthalmology Save Sight Institute The University of Sydney Sydney New South Wales Australia
| |
Collapse
|
18
|
Gabrielle P, Nguyen V, Creuzot‐Garcher C, Miguel L, Alforja S, Sararols L, Casaroli‐Marano RP, Zarranz‐Ventura J, Gillies M, Arnold J, Barthelmes D. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry. Acta Ophthalmol 2022; 100:e288-e296. [PMID: 33960115 PMCID: PMC9290852 DOI: 10.1111/aos.14893] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 03/08/2021] [Accepted: 04/10/2021] [Indexed: 01/22/2023]
Abstract
Purpose To report the 24‐month outcomes of vascular endothelial growth factor (VEGF) inhibitors for myopic choroidal neovascularization (mCNV) in predominantly Caucasian eyes in routine clinical practice. Methods Retrospective analysis of treatment‐naïve eyes starting intravitreal injection of VEGF inhibitors of either bevacizumab (1.25 mg) or ranibizumab (0.5 mg) for mCNV from 1 January 2006 to 31 May 2018 that were tracked in the Fight Retinal Blindness! registry. Results We identified 203 eyes (bevacizumab–85 and ranibizumab–118) of 189 patients. The estimated mean (95% CI) change in VA over 24 months for all eyes using longitudinal models was +8 (5, 11) letters with a median (Q1, Q3) of 3 (2, 5) injections given mostly during the first year. The estimated mean change in VA at 24 months was similar between bevacizumab and ranibizumab [+9 (5, 13) letters for bevacizumab versus +9 (6, 13) letters for ranibizumab; p = 0.37]. Both agents were also similar in the mCNV activity outcomes, treatment frequency and visit frequency. Conclusions The 24‐month treatment outcomes of VEGF inhibitors for mCNV were favourable in this largest series yet reported of predominantly Caucasian eyes in routine clinical practice, with approximately two lines of visual gain and a median of three injections given mostly during the first year. These outcomes are similar to those reported for predominantly Asian eyes. Bevacizumab appeared to be as safe and effective as ranibizumab.
Collapse
Affiliation(s)
- Pierre‐Henry Gabrielle
- Discipline of Ophthalmology Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
- Department of Ophthalmology Dijon University Hospital Dijon France
| | - Vuong Nguyen
- Discipline of Ophthalmology Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
| | | | - Lucia Miguel
- Clinical Institute of Ophthalmology (ICOF) Hospital Clinic Barcelona Spain
| | - Socorro Alforja
- Clinical Institute of Ophthalmology (ICOF) Hospital Clinic Barcelona Spain
| | | | - Ricardo P. Casaroli‐Marano
- Clinical Institute of Ophthalmology (ICOF) Hospital Clinic Barcelona Spain
- University of Barcelona Barcelona Spain
- August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Barcelona Spain
| | - Javier Zarranz‐Ventura
- Clinical Institute of Ophthalmology (ICOF) Hospital Clinic Barcelona Spain
- August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Barcelona Spain
| | - Mark Gillies
- Discipline of Ophthalmology Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
| | | | - Daniel Barthelmes
- Discipline of Ophthalmology Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia
- Department of Ophthalmology University Hospital Zurich University of Zurich Zurich Switzerland
| |
Collapse
|
19
|
Grechenig C, Reiter GS, Riedl S, Arnold J, Guymer R, Gerendas BS, Bogunović H, Schmidt-Erfurth U. IMPACT OF RESIDUAL SUBRETINAL FLUID VOLUMES ON TREATMENT OUTCOMES IN A SUBRETINAL FLUID-TOLERANT TREAT-AND-EXTEND REGIMEN. Retina 2021; 41:2221-2228. [PMID: 33830960 DOI: 10.1097/iae.0000000000003180] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE To investigate associations between residual subretinal fluid (rSRF) volumes, quantified using artificial intelligence and treatment outcomes in a subretinal fluid (SRF)-tolerant treat-and-extend (T&E) regimen in neovascular age-related macular degeneration. METHODS Patients enrolled in the prospective, multicenter FLUID study randomized in an SRF-tolerant T&E regimen were examined by spectral-domain optical coherence tomography and tested for best-corrected visual acuity (BCVA). Intraretinal fluid and SRF volumes were quantified using artificial intelligence tools. In total, 375 visits of 98 patients were divided into subgroups: extended intervals despite rSRF and extended intervals without fluid. Associations between BCVA change, SRF volume, subgroups, and treatment intervals were estimated using linear mixed models. RESULTS In extended intervals despite rSRF, increased SRF was associated with reduced BCVA at the next visit in the central 1 mm (-0.138 letters per nL; P = 0.014) and 6 mm (-0.024 letters per nL; P = 0.049). A negative association between increased interval and BCVA change was found for rSRF in 1 mm and 6 mm (-0.250 and -0.233 letter per week interval, respectively; both P < 0.001). Extended intervals despite rSRF had significantly higher SRF volumes in the central 6 mm at the following visit (P = 0.002). CONCLUSION Artificial intelligence-based analysis of extended visits despite rSRF demonstrated increasing SRF volumes associated with BCVA loss at the consecutive visit. This negative association contributes to the understanding of rSRF volumes on treatment outcomes in neovascular age-related macular degeneration.
Collapse
Affiliation(s)
- Christoph Grechenig
- Department of Ophthalmology and Optometry, Christian Doppler Laboratory for Ophthalmic Image Analysis, Medical University of Vienna, Vienna, Austria
| | - Gregor S Reiter
- Department of Ophthalmology and Optometry, Christian Doppler Laboratory for Ophthalmic Image Analysis, Medical University of Vienna, Vienna, Austria
| | - Sophie Riedl
- Department of Ophthalmology and Optometry, Christian Doppler Laboratory for Ophthalmic Image Analysis, Medical University of Vienna, Vienna, Austria
| | | | - Robyn Guymer
- Department of Surgery (Ophthalmology), Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia
| | - Bianca S Gerendas
- Department of Ophthalmology and Optometry, Christian Doppler Laboratory for Ophthalmic Image Analysis, Medical University of Vienna, Vienna, Austria
| | - Hrvoje Bogunović
- Department of Ophthalmology and Optometry, Christian Doppler Laboratory for Ophthalmic Image Analysis, Medical University of Vienna, Vienna, Austria
| | - Ursula Schmidt-Erfurth
- Department of Ophthalmology and Optometry, Christian Doppler Laboratory for Ophthalmic Image Analysis, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
20
|
Abstract
OBJECTIVE In our canine scent detection research involving a specific volatile organic compound (VOC) associated with human epileptic seizure, we began to suspect involvement of the primitive neural networks associated with production of a previously undescribed human alarm pheromone as the origin of our seizure scent. We hypothesized that if we presented fear-scented sweat to our canine seizure scent detection team, and they identified the fear scent as their seizure scent, then that would suggest that they are identical compounds. METHODS Following consent and approval, sweat samples taken from volunteers associated with the Brooke Gordon Comprehensive Epilepsy Center at Denver Health were processed by the Canine Assistants (CA) service dog team that had been imprinted to recognize the unique seizure scent from our previous study. In part one, sweat samples were collected from subjects, who had no prior history of epilepsy or seizures, under two different testing environments: watching a scary movie (It) and a neutral/comedy movie (Airplane!). In part two, a larger follow-up study utilizing fear sweat, exercise sweat, epilepsy sweat, and other distractor scents were provided in a multiple choice paradigm to better understand the inter-rater reliability of the canine responses. RESULTS In part one, our canine seizure scent detection team identified fear-scented sweat samples as their seizure scent in 4 of 5 study participants. There was almost perfect agreement of seizure scent detection during fear scent trials between the canine seizure scent detectors with a kappa value of 0.814 (95% CI: 0.668-0.960). In part two, (utilizing eleven different subjects) our canine scent detection team identified samples of either fear or seizure sweat with a sensitivity of 82% and a specificity of 100% (no false positives) from among the multiple choices offered. Additionally, there was 92% agreement between the members of the canine scent detection team. SIGNIFICANCE While this hypothesis testing study is small and deserves replication, it confirms that the Canine Assistants seizure scent detection team consistently and accurately identified fear-scented sweat as their seizure scent, implying that the VOC, menthone, is common to both conditions. This further implies that human seizure propagation and fear network circuitry may share a common anatomy, and that menthone may not only be an early seizure biomarker, but a newly described human alarm pheromone.
Collapse
Affiliation(s)
- E H Maa
- Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States; Department of Neurology, University of Colorado, 1635 Aurora Court, Aurora, CO 80045, United States.
| | - J Arnold
- Canine Assistants, 3160 Francis Road, Milton, GA 30004, United States
| | - C K Bush
- Department of Neurology, University of Colorado, 1635 Aurora Court, Aurora, CO 80045, United States
| |
Collapse
|
21
|
Pepple S, Arnold J, Vital E, Rawstron A, Pease C, Dass S, Emery P, MD Yusof MY. AB0293 IDENTIFYING PREDICTORS OF SHORT-TERM RESPONSE TO RITUXIMAB IN PRIMARY SJOGREN’S SYNDROME. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Randomised controlled trials of rituximab (RTX) in primary Sjogren’s syndrome (pSS) have aimed to alleviate glandular symptoms and fatigue with only limited data on efficacy/effectiveness of the initial and repeat cycles of RTX on extra-glandular pSS.Objectives:To assess the effectiveness of RTX on extra-glandular symptoms and identify predictors of short-term response with a view to personalised B-cell depleting therapy in patients with pSS.Methods:An observational study was conducted in 40 consecutive RTX-treated pSS patients in a single centre for over 15 years. All patients fulfilled the 2002 AEG criteria and were CCP negative. Clinical response at 6 months was defined as ≥3 reduction of ESSDAI from baseline. B-cell subsets were measured using highly sensitive flow cytometry. Predictors of short-term response were analysed using penalised logistic regression.Results:38/40 (95%) patients were female, mean (SD) Age 54 (13.7) years, median (IQR) disease duration 5 (2-9) years, 39/40 (98%) had positive ANA, 26/40 (65%) were on concomitant immunosuppressant (IS). Mean (SD) ESSDAI at RTX initiation was 11.5 (6.7); main domains for RTX were articular (73%), skin (23%), PNS (15%) and muscular (15%). 169 RTX cycles were administered with a total follow-up of 165PY. In Cycle 1 (C1) RTX, the proportion of patient achieving ESSDAI response from baseline was 29/40 (73%; 95% CI 58-87). There were significant reductions in ESSDAI, daily prednisolone dose and IgG levels at 6 months (all p<0.05). Of C1 responders, 23/29 received retreatment on clinical relapse; of which 8/23 (35%) lost response [secondary non-depletion non response (2NDNR) associated with anti-RTX antibodies=4 (17%) as we previously observed in SLE[1], side effects=2, ineffective=2]. Of C1 non-responders, 9/11 were retreated but only 2/9 responded in C2. Overall, 13/40 (33%) discontinued RTX within two cycles. In multivariable analysis, concomitant IS and achieving compete B-cell depletion in C1 reduced non-response to RTX (Table 1).Conclusion:All pSS patients should be prescribed concomitant immunosuppressant with RTX and therapy should aim to achieve complete depletion. About 1 in 6 pSS patients lose response in repeat cycles which is associated with 2NDNR phenomenon. The use of humanised or type 2 anti-CD20mAbs should overcome these issues and improve the clinical response of extra-glandular pSS.References:[1]Md Yusof et al. ARD 2017 (2520 characters – allowed around 2600 as Table 1 is included too)Table 1.MVA logistic regression of risk factors for RTX non-responsePredictorsContinued Response (N=27)Non-response within 2 RTX Cycles (N=13)UnivariableOR (95% CI); p-valueMultivariableOR (95% CI); p-valueAge, mean (SD) per 10 years55 (14)52 (12)0.87 (0.53-1.41); 0.572Excluded from final modelDisease duration, median (IQR)5 (2-9)6 (3-9)0.97 (0.87-1.08); 0.565Excluded from final modelConcomitant IS, %81.5%30.8%0.10 (0.02-0.46); 0.0030.07 (0.01-0.52); 0.010IgG, mean (SD), g/L15.5 (6.3)18.4 (5.8)1.08 (0.97-1.20); 0.1751.13 (0.97-1.32); 0.116Clinical ESSDAI, median (IQR)10 (6-16)8 (6-10)0.96 (0.85-1.08); 0.4870.91 (0.79-1.05); 0.185Baseline Plasmablast (x1000),109 cells/L, median(IQR)2.6 (1 -5.2)2.3 (1.6-9.5)1.00 (0.94-1.07); 0.885Excluded from final modelComplete B-cell depletion post-RTX, %55.6%8.5%0.07 (0.01-0.64); 0.0180.04 (0.02-0.82); 0.036Disclosure of Interests:Sophanit Pepple: None declared, Jack Arnold: None declared, Edward Vital Grant/research support from: Dr Vital has received honoraria and research grant support from Roche, Andrew Rawstron: None declared, Colin Pease: None declared, Shouvik Dass Grant/research support from: Dr Dass has received honoraria from Roche, Paul Emery Consultant of: Professor Emery has received consultant fees from Roche., Grant/research support from: Professor Emery has received research grants paid to his employer from Roche., Md Yuzaiful Md Yusof: None declared
Collapse
|
22
|
Arnold J, Vital E, Dass S, Aslam A, Rawstron A, Savic S, Emery P, MD Yusof MY. OP0057 A PERSONALISED RITUXIMAB RETREATMENT APPROACH BASED ON CLINICAL AND B-CELL BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Time-to-relapse after rituximab for ANCA-associated vasculitis (AAV) is variable and optimal retreatment strategy has been unclear. We previously showed that repopulation of naïve B-cells at 6 months predicts sustained response [1].Objectives:In AAV following rituximab induction, to evaluate clinical and B-cell predictors of relapse in order to develop a retreatment algorithm.Methods:An observational study was conducted in 60 rituximab-treated AAV patients followed for over 10 years. Complete response (CR) was defined as Birmingham Vasculitis Activity Score v3.0 = 0. Retreatment was given on clinical relapse, defined as new features or worsening of persistent disease (not by biomarker status). Peripheral B-cell subsets were measured using highly sensitive flow cytometry. Predictors were tested using multivariable Cox-Regression.Results:Median times-to-retreatment for rituximab cycles 1-5 were 87, 71, 65, 59 and 86 weeks. Over 417 patient-years follow-up, 137 relapses occurred in 50 patients; 16 (in 14 patients) were major (renal=7, neurological=4, ENT=3 and respiratory=2). The major-relapse rate was 3.8/100 patient-years. In multivariable analysis, concomitant immunosuppressant [HR 0.48 (95% CI 0.24–0.94)], achieving CR [0.24 (0.12–0.50)] and naïve B-cell repopulation at 6 months [0.43 (0.22–0.84)] were associated with longer time-to-relapse. Higher baseline memory B-cells [1.01 (1.00–1.02)] were associated with a shorter time-to-relapse. AUROC for prediction of time-to-relapse was greater if guided by naïve B-cell repopulation than if ANCA and/or CD19+ return at 6 months had been used, 0.82 and 0.52 respectively.Conclusion:These data suggest that all patients should receive concomitant oral immunosuppressant. Those with incomplete response or with absent naïve B-cells should be retreated at 6 months. Patients with complete response and naïve repopulation at 6 months should not receive fixed retreatment. This algorithm could reduce hypogammaglobulinaemia due to unnecessary retreatment.Figure 1.A personalised retreatment algorithm for rituximab in ANCA-associated vasculitisReferences:[1]Md Yusof et al. Annals of rheumatic diseases (2015) PMID: 25854586.Disclosure of Interests:Jack Arnold: None declared, Edward Vital Speakers bureau: Roche, GSK and AstraZeneca, Consultant of: Roche, GSK and AstraZeneca, Grant/research support from: Roche, GSK and AstraZeneca, Shouvik Dass Speakers bureau: Roche and GSK, Aamir Aslam: None declared, Andrew Rawstron: None declared, Sinisa Savic: None declared, Paul Emery Speakers bureau: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, Consultant of: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, Grant/research support from: Abbott, BMS, Pfizer, MSD and Roche., Md Yuzaiful Md Yusof: None declared
Collapse
|
23
|
Hunt AR, Nguyen V, Creuzot-Garcher CP, Alforja S, Gabrielle PH, Zarranz-Ventura J, Guillemin M, Fraser-Bell S, Casaroli Marano RP, Arnold J, McAllister IL, O'Toole L, Gillies MC, Barthelmes D, Mehta H. Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry. Br J Ophthalmol 2021; 106:1178-1184. [PMID: 33712484 DOI: 10.1136/bjophthalmol-2020-318491] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Revised: 02/12/2021] [Accepted: 03/04/2021] [Indexed: 12/22/2022]
Abstract
BACKGROUND/AIMS To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months. METHODS A multicentre, international, database observational study recruited 322 eyes initiating therapy in real-world practice over 5 years. The main outcome measure was mean change in EDTRS letter scores of visual acuity (VA). Secondary outcomes included anatomic outcomes, percentage of eyes with VA >6/12 (70 letters), number of injections and visits, time to first inactivity, switching or non-completion. RESULTS Generalised mixed effect models demonstrated that mean (95% CI) adjusted 12-month VA changes for ranibizumab and aflibercept were similar (+10.8 (8.2 to 13.4) vs +10.9 (8.3 to 13.5) letters, respectively, p=0.59). The mean adjusted change in central subfield thickness (CST) was greater for aflibercept than ranibizumab (-170 (-153 to -187) µm vs -147 (-130 to -164) µm, respectively, p=0.001). The overall median (Q1, Q3) of 7 (4, 8) injections and 9 (7, 11) visits was similar between treatment groups. First grading of inactivity occurred sooner with aflibercept (p=0.01). Switching was more common from ranibizumab (37 eyes, 23%) than from aflibercept (17 eyes, 11%; p=0.002). CONCLUSION Visual outcomes at 12 months in this direct comparison of ranibizumab and aflibercept for BRVO in real-world practice were generally good and similar for the 2 drugs, despite a greater effect of aflibercept on CST and time to first grading of inactivity.
Collapse
Affiliation(s)
- Adrian R Hunt
- Medical Retina, Westmead Hospital, Westmead, New South Wales, Australia .,Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
| | - Vuong Nguyen
- Clinical Ophthalmology & Eye Health, The University of Sydney, Sydney, New South Wales, Australia
| | | | - Socorro Alforja
- Institut Clínic de Oftalmologia (ICOF), Hospital Clinic de Barcelona, Barcelona, Spain
| | - Pierre-Henry Gabrielle
- Ophthalmology, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.,Eye and Nutrition Research Group, Centre des Sciences du Goût et de l'Alimentation, INRA Centre de Dijon, Dijon, Bourgogne, France
| | | | - Martin Guillemin
- Ophthalmology, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France
| | - Samantha Fraser-Bell
- Clinical Ophthalmology & Eye Health, The University of Sydney, Sydney, New South Wales, Australia
| | | | - Jennifer Arnold
- Marsden Eys Specialists, Parramatta, Greater Western Sydney, Australia
| | - Ian L McAllister
- Lions Eye Institute, The University of Western Australia, Nedlands, Western Australia, Australia
| | | | - Mark C Gillies
- Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
| | - Daniel Barthelmes
- UniversitatsSpital Zurich Augenklinik und Poliklinik, Zurich, ZH, Switzerland
| | - Hemal Mehta
- Medical Retina, Sydney Eye Hospital, Sydney, New South Wales, Australia.,Medical Retina, Moorfields Eye Hospital, London, UK
| |
Collapse
|
24
|
Maa E, Arnold J, Ninedorf K, Olsen H. Canine detection of volatile organic compounds unique to human epileptic seizure. Epilepsy Behav 2021; 115:107690. [PMID: 33360399 DOI: 10.1016/j.yebeh.2020.107690] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 11/30/2020] [Accepted: 12/01/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Literature accounts of service dogs alerting patients prior to their seizures are a mix of historically poor quality data and confounding diagnoses. In a group of epilepsy patients, Canine Assistants and Florida International University characterized a unique scent combination of volatile organic compounds present during the immediate postictal period, but never at other times. The current study was designed to confirm prospectively if this unique scent, and potential biomarker, can: (1) be detected in an epilepsy monitoring unit (EMU), (2) whether this scent is present with nonepileptic seizures, and (3) whether this scent also precedes the clinical-electrographic seizure. METHODS Following consent and approval, sweat samples taken from EMU admissions at Denver Health Medical Center were sent to Canine Assistants in Georgia. Their team of service dogs, who had been imprinted to recognize the unique scent, were then asked to process these sweat samples in a simple yes/no identification paradigm. RESULTS Sixty unique subjects were enrolled over a two-year period. In the first part of this study, a total of 298 ictal sweat samples of 680 total observations were collected. The dogs had a 93.7% (OR: 14.89, 95% CI: 9.27, 23.90) probability of correctly distinguishing between ictal and interictal sweat samples. In the nonepileptic seizure population, 18 of the 19 NES events that were accompanied by sweat sample collections were not associated with identification of the unique seizure scent. In the second part of the study, in which subjects had samples collected every hour, dogs identified the unique seizure scent presence before 78.7% of all seizures captured, at a probability of 82.2% (OR: 4.60, 95% CI: 0.98, 21.69) of a positive detection predicting a seizure. The average duration of the warning phase of the scent was 68.2 min. The average duration of the tail phase of the scent faded after 81 min. SIGNIFICANCE This study confirms the unique seizure scent identified by Canine Assistants and FIU may be collected and recognized by dogs trained to do so, in a prospective manner. A significant number of seizures appear to be associated with the unique scent presence prior to clinical-electrical onset of the seizure itself, and therefore further study of this biomarker is warranted.
Collapse
Affiliation(s)
- Edward Maa
- Comprehensive Epilepsy Center, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States; Neurology, University of Colorado, 1635 Aurora Court, Aurora, CO 80045, United States.
| | - Jennifer Arnold
- Canine Assistants, 3160 Francis Road, Milton, GA 30004, United States
| | - Katherine Ninedorf
- Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States.
| | - Heather Olsen
- Rocky Mountain Poison and Drug Safety at Denver Health Medical Center, 1391 Speer Boulevard #600, Denver, CO 80204, United States.
| |
Collapse
|
25
|
Simpson J, Brasher MI, Arnold J, Endom E, Doughty CB. Simulation of an Atypical Presentation of Necrotizing Enterocolitis in the Emergency Department. Cureus 2021; 13:e12604. [PMID: 33585094 PMCID: PMC7872491 DOI: 10.7759/cureus.12604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Accepted: 01/07/2021] [Indexed: 11/05/2022] Open
Abstract
Necrotizing enterocolitis (NEC) is a gastrointestinal emergency most commonly seen in premature infants, but equally important to recognize in term infants. Early diagnosis and management is critical to achieving optimal patient outcomes. This report outlines a simulation of the challenging scenario of a term infant presenting to the emergency center with NEC as a result of bacteremia and sepsis due to a urinary tract infection (UTI). This simulation can be used for teaching different levels of learners including novice, intermediate, and advanced. It focuses on the presentation, diagnosis, and emergent management of NEC, and additionally incorporates Pediatric Advanced Life Support (PALS) for more advanced learners.
Collapse
Affiliation(s)
- Jennifer Simpson
- Pediatric Emergency Medicine, Baylor College of Medicine, Houston, USA
| | - Maya I Brasher
- Neonatal and Perinatal Medicine, University of Texas Health Science Center at Houston, Houston, USA
| | - Jennifer Arnold
- Neonatal Medicine, Johns Hopkins All Children's Hospital, St. Petersburg, USA
| | - Erin Endom
- Pediatric Emergency Medicine, Baylor College of Medicine, Houston, USA
| | - Cara B Doughty
- Pediatric Emergency Medicine, Baylor College of Medicine, Houston, USA
| |
Collapse
|
26
|
Arnold J, Kanagala P, Budgeon C, Jerosch-Herold M, Singh A, Khan J, Gulsin G, Squire I, Ng L, McCann G. Prevalence of microvascular dysfunction and association with clinical outcomes in heart failure with preserved ejection fraction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of symptomatic heart failure. A recently proposed paradigm for the pathophysiology of HFpEF postulates a central inflammatory aetiology with coronary microvascular function at its core. However, the pathophysiological and clinical significance of microvascular dysfunction in HFpEF remains uncertain.
Purpose
Utilising cardiovascular magnetic resonance (CMR), we sought to (1) quantify coronary microvascular function, (2) evaluate the impact of microvascular dysfunction and fibrosis on long-term clinical outcomes and (3) examine the relationship between myocardial perfusion and fibrosis.
Methods
In a prospective, observational study, 147 subjects (104 HFpEF without a prior history or CMR evidence of coronary artery disease, and 43 asymptomatic controls) underwent multiparametric CMR, comprising left ventricular volumetric assessment, absolute quantitation of myocardial blood flow [MBF] during adenosine stress (140mcg/kg/min) and at rest, and evaluation of diffuse myocardial fibrosis (extracellular volume [ECV]). The primary endpoint was the composite of death or hospitalisation with heart failure.
Results
104 HFpEF patients (mean age 73±9 years, mean ejection fraction 56%) and 43 controls (mean age 73±5 years, mean ejection fraction 58%) were studied. There was no significant difference in resting MBF (1.10±0.42ml/min/g in HFpEF subjects vs 1.00±0.38 ml/min/g in controls, p=0.23), though hyperaemic MBF was lower in HFpEF subjects (1.66±0.68 ml/min/g vs 1.97±0.59 ml/min/g, p=0.01). Myocardial perfusion reserve [MPR] was also lower in HFpEF subjects (1.73±0.75 vs 2.22±0.76; p<0.01). Microvascular dysfunction (defined as MPR<2.0) was present in 70% of HFpEF patients (versus 33% of controls, p<0.01). During median follow-up of 3.4 years, there were 46 composite events. MPR was predictive of clinical outcome (one unit increase – hazard ratio [HR] 0.57; 95% CI 0.35–0.92; p=0.02), as was ECV (one standard deviation [SD] increase – HR 1.65; 95% CI 1.14–2.39; p=0.01). However, there was no significant linear correlation between MPR and diffuse fibrosis (r<0.01, p=0.99).
Conclusion
Microvascular dysfunction is highly prevalent in HFpEF and is associated with adverse clinical outcomes. The lack of correlation between abnormal myocardial perfusion and fibrosis challenges the assertion of a direct causal link between these entities.
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): NIHR, BHF
Collapse
Affiliation(s)
- J Arnold
- University of Leicester, Leicester, United Kingdom
| | - P Kanagala
- University of Leicester, Leicester, United Kingdom
| | - C.A Budgeon
- University of Leicester, Leicester, United Kingdom
| | | | - A.S Singh
- University of Leicester, Leicester, United Kingdom
| | - J.N Khan
- University of Leicester, Leicester, United Kingdom
| | - G.S Gulsin
- University of Leicester, Leicester, United Kingdom
| | - I.B Squire
- University of Leicester, Leicester, United Kingdom
| | - L.L Ng
- University of Leicester, Leicester, United Kingdom
| | - G.P McCann
- University of Leicester, Leicester, United Kingdom
| |
Collapse
|
27
|
Fung AT, Tran T, Lim LL, Samarawickrama C, Arnold J, Gillies M, Catt C, Mitchell L, Symons A, Buttery R, Cottee L, Tumuluri K, Beaumont P. Local delivery of corticosteroids in clinical ophthalmology: A review. Clin Exp Ophthalmol 2020; 48:366-401. [PMID: 31860766 PMCID: PMC7187156 DOI: 10.1111/ceo.13702] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 11/21/2019] [Accepted: 12/09/2019] [Indexed: 12/22/2022]
Abstract
Locally administered steroids have a long history in ophthalmology for the treatment of inflammatory conditions. Anterior segment conditions tend to be treated with topical steroids whilst posterior segment conditions generally require periocular, intravitreal or systemic administration for penetration. Over recent decades, the clinical applications of periocular steroid delivery have expanded to a wide range of conditions including macular oedema from retino-vascular conditions. Formulations have been developed with the aim to provide practical, targeted, longer-term and more efficacious therapy whilst minimizing side effects. Herein, we provide a comprehensive overview of the types of periocular steroid delivery, their clinical applications in ophthalmology and their side effects.
Collapse
Affiliation(s)
- Adrian T. Fung
- Westmead Clinical SchoolDiscipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South WalesAustralia
- Department of Ophthalmology, Faculty of Medicine and Health SciencesMacquarie UniversitySydneyNew South WalesAustralia
- Save Sight InstituteCentral Clinical School, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South WalesAustralia
| | - Tuan Tran
- Save Sight InstituteCentral Clinical School, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South WalesAustralia
| | - Lyndell L. Lim
- Royal Victorian Eye and Ear HospitalMelbourneVictoriaAustralia
- Centre for Eye Research AustraliaMelbourneVictoriaAustralia
- University of MelbourneMelbourneVictoriaAustralia
| | - Chameen Samarawickrama
- Westmead Clinical SchoolDiscipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South WalesAustralia
- Save Sight InstituteCentral Clinical School, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South WalesAustralia
- Liverpool Clinical School, Faculty of MedicineUniversity of New South WalesSydneyNew South WalesAustralia
| | | | - Mark Gillies
- Save Sight InstituteCentral Clinical School, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South WalesAustralia
| | - Caroline Catt
- Save Sight InstituteCentral Clinical School, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South WalesAustralia
- Children's Hospital WestmeadWestmeadNew South WalesAustralia
| | | | | | | | - Lisa Cottee
- Eye Doctors Mona ValeSydneyNew South WalesAustralia
| | - Krishna Tumuluri
- Westmead Clinical SchoolDiscipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South WalesAustralia
- Department of Ophthalmology, Faculty of Medicine and Health SciencesMacquarie UniversitySydneyNew South WalesAustralia
- Save Sight InstituteCentral Clinical School, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South WalesAustralia
| | | |
Collapse
|
28
|
Gillies MC, Nguyen CL, Nguyen V, Daien V, Cohn A, Banerjee G, Arnold J. Reply. Ophthalmology 2020; 127:e21-e22. [DOI: 10.1016/j.ophtha.2019.10.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Accepted: 10/29/2019] [Indexed: 11/26/2022] Open
|
29
|
Gillies M, Arnold J, Bhandari S, Essex RW, Young S, Squirrell D, Nguyen V, Barthelmes D. Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. Am J Ophthalmol 2020; 210:116-124. [PMID: 31606444 DOI: 10.1016/j.ajo.2019.10.007] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 10/02/2019] [Accepted: 10/02/2019] [Indexed: 10/25/2022]
Abstract
PURPOSE To report and compare 10-year treatment outcomes of vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) from Australia and New Zealand (ANZ) and Switzerland. DESIGN Retrospective, comparative, interventional case series. METHODS We analyzed 712 treatment-naive eyes (ANZ, n = 474; Switzerland, n = 321) starting anti-VEGF for nAMD in routine clinical practice between January 1, 2006, and December 31, 2008, tracked in the prospectively designed observational database, the Fight Retinal Blindness! registry. The primary outcome was mean change in visual acuity (VA [in logMAR letters]) in eyes that completed 10 years of treatment. RESULTS The mean VA in 132 eyes (28%) from ANZ patients who completed 10 years of treatment dropped by 0.9 letters from baseline (95% confidence interval [CI], -4.9 to 3.1; P = 0.7) with 42% achieving ≥20/40, whereas the 37 eyes (12%) from Swiss subjects lost 14.9 letters (95% CI, -24 to -5.7; P < 0.001) with 35% achieving ≥20/40. Eyes from ANZ patients received more injections than eyes from Swiss subjects over 10 years (a median of 53 vs 42, respectively) from fewer visits with better disease control (proportion of visits with active disease: 38% vs 69%, respectively), suggesting a treat-and-extend regimen versus a pro re nata regimen (treatment given only when the lesion is active). Macular atrophy and subretinal fibrosis were the main reasons for 10 letter loss in the subset of eyes analyzed retrospectively. The mean VA of eyes from both regions that discontinued treatment within 10 years had fallen below the baseline at their final visit. CONCLUSIONS Eyes with nAMD may achieve satisfactory long-term visual outcomes if they receive adequate treatment. Central macular atrophy does not develop universally in eyes receiving long-term treatment with VEGF inhibitors as previously feared. Visual outcomes were better in eyes from ANZ patients, likely because they received more injections.
Collapse
|
30
|
Kumar D, Vachharajani AJ, Wertheimer F, Vergales B, Glass K, Dannaway D, Winter L, Delaney H, Ganster A, Arnold J, Urban A, Johnston L, Bruno C, Gray MM, Sawyer T. Boot camps in neonatal-perinatal medicine fellowship programs: A national survey. J Neonatal Perinatal Med 2020; 12:231-237. [PMID: 30829620 DOI: 10.3233/npm-18117] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Simulation is widely used in graduate medical education. A prior survey showed that 80% of Neonatal-Perinatal Medicine (NPM) fellowship programs in the U.S. use simulation. There are multiple ways to provide simulation-based education. One such method is through intensive simulation-based education sessions held at the beginning of a training program, common called 'boot camps'. The aim of this study was to describe the use of simulation-based boot camps in NPM fellowship programs. METHODS Survey study of Accreditation Council for Graduate Medical Education (ACGME) accredited NPM fellowships in the U.S. RESULTS Fifty-nine of 98 programs (60%) responded. Thirty six (61%) participated in 1st year fellow boot camps, which focused on procedural skills and newborn resuscitation. Nearly half of programs participated in regional boot camps. Most boot camps were one or two days long. Eleven programs (19%) held 2nd or 3rd year fellow boot camps, which focused on advanced resuscitation and communication. Barriers included lack of faculty protected time (57%), funding (39%), and lack of faculty experience (31%). CONCLUSIONS A majority of ACGME accredited NPM fellowships participate in 1st year fellows' boot camps. Many participate in regional boot camps. A few programs have 2nd or 3rd year fellow boot camps. Lack of time, funding, and faculty experience were common barriers.
Collapse
Affiliation(s)
- D Kumar
- Department of Pediatrics, Division of Neonatology, Case Western Reserve University School of Medicine, MetroHealth Medical Center, Cleveland, OH, USA
| | - A J Vachharajani
- Department of Pediatrics, Division of Newborn Medicine, Washington University in St. Louis and St. Louis Children's Hospital, St. Louis, MO, USA
| | - F Wertheimer
- Department of Pediatrics, Division of Neonatology, Keck School of Medicine of USC, Los Angeles, CA, USA
| | - B Vergales
- Department of Pediatrics, Division of Neonatology, University of Virginia Health System, Charlottesville, VA, USA
| | - K Glass
- Department of Pediatrics, Division of Neonatal-Perinatal Medicine, Penn State College of Medicine, Penn State Health Children's Hospital, Hershey, PA, USA
| | - D Dannaway
- Department of Pediatrics, Section of Neonatal-Perinatal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - L Winter
- Department of Pediatrics, Division of Neonatology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - H Delaney
- Department of Pediatrics, Division of Neonatology, Brooke Army Medical Center, San Antonio, TX, USA
| | - A Ganster
- Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, USA
| | - J Arnold
- Department of Pediatrics, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA
| | - A Urban
- Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - L Johnston
- Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA
| | - C Bruno
- Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA
| | - M M Gray
- Department of Pediatrics, Division of Neonatology, University of Washington School of Medicine and Seattle Children's Hospital. Seattle, WA, USA
| | - T Sawyer
- Department of Pediatrics, Division of Neonatology, University of Washington School of Medicine and Seattle Children's Hospital. Seattle, WA, USA
| | | |
Collapse
|
31
|
Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D. Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry. Ophthalmology 2019; 127:369-376. [PMID: 31757494 DOI: 10.1016/j.ophtha.2019.10.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Revised: 10/04/2019] [Accepted: 10/04/2019] [Indexed: 12/20/2022] Open
Abstract
PURPOSE Ranibizumab and aflibercept are both approved for the treatment of neovascular age-related macular degeneration (nAMD). Herein, we compare the 3-year treatment outcomes of the 2 in routine clinical practice. DESIGN Retrospective analysis of data from a prospectively designed observational outcomes registry, the Fight Retinal Blindness! PROJECT PARTICIPANTS Treatment-naïive eyes starting nAMD treatment from December 1, 2013 through December 31, 2015, with either ranibizumab or aflibercept that were tracked in the registry. METHODS Visual acuity (VA) was analyzed annually in completers (those who completed 3 years of treatment) and in all eyes (completers, noncompleters, and those who switched treatment ). MAIN OUTCOME MEASURES The primary outcome was mean change in VA (number of letters read on a logarithm of the minimum angle of resolution chart). RESULTS A total of 965 eyes of 897 patients (ranibizumab, 499 eyes [469 patients]; aflibercept, 466 eyes [432 patients) were identified. The mean VA and the type of the choroidal neovascularization (CNV) at the start of treatment were similar between the 2 groups. The group receiving ranibizumab was older. The crude mean VA change of +1.5 letters (95% confidence interval [CI], 0-3.1 letters) in the ranibizumab group and of +1.6 letters (95% CI, -0.2 to 3.3 letters; P = 0.97) in the aflibercept group at 3 years in all eyes was similar, as was the adjusted mean VA change, +0.3 letters (95% CI, -1.5 to 2.0 letters) versus +1.0 letters (95% CI, -0.7 to 2.8 letters; P = 0.66). Both treatment groups received a median of 18 injections from a median of 21 clinical visits. The adjusted proportion of clinical visits when the CNV was graded active over 3 years was similar between ranibizumab (43%) and aflibercept (51%; P = 0.9). More switches from ranibizumab to aflibercept (P < 0.001) took place than vice versa. The proportion of eyes that did not complete 3 years of treatment in each of the group was similar (P = 0.21). CONCLUSIONS Neither ranibizumab nor aflibercept was superior to the other in terms of VA outcomes and treatment frequency at 3 years for nAMD.
Collapse
Affiliation(s)
- Sanjeeb Bhandari
- Save Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, Australia.
| | - Vuong Nguyen
- Save Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, Australia
| | | | | | | | - Mark Gillies
- Save Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, Australia
| | - Daniel Barthelmes
- Save Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| |
Collapse
|
32
|
Affiliation(s)
- Jennifer Arnold
- Division of Neonatology, Johns Hopkins Medicine, Johns Hopkins All Children's Hospital, St Petersburg, Florida
| | - Melissa Cashin
- Simulation Education, Texas Children's Hospital, Houston
| | - Oluyinka O Olutoye
- Surgery, Pediatrics and Obstetrics & Gynecology, Baylor College of Medicine, Houston, Texas
| |
Collapse
|
33
|
Colman N, Doughty C, Arnold J, Stone K, Reid J, Dalpiaz A, Hebbar KB. Simulation-based clinical systems testing for healthcare spaces: from intake through implementation. Adv Simul (Lond) 2019; 4:19. [PMID: 31388455 PMCID: PMC6676572 DOI: 10.1186/s41077-019-0108-7] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 07/18/2019] [Indexed: 11/17/2022] Open
Abstract
Healthcare systems are urged to build facilities that support safe and efficient delivery of care. Literature demonstrates that the built environment impacts patient safety. Design decisions made early in the planning process may introduce flaws into the system, known as latent safety threats (LSTs). Simulation-based clinical systems testing (SbCST) has successfully been incorporated in the post-construction evaluation process in order to identify LSTs prior to patient exposure and promote preparedness, easing the transition into newly built facilities. As the application of simulation in healthcare extends into the realm of process and systems testing, there is a need for a standardized approach by which to conduct SbCST in order to effectively evaluate newly built healthcare facilities. This paper describes a systemic approach by which to conduct SbCST and provides documentation and evaluation tools in order to develop, implement, and evaluate a newly built environment to identify LSTs and system inefficiencies prior to patient exposure.
Collapse
Affiliation(s)
- Nora Colman
- Department of Pediatrics, Division of Pediatric Critical Care, Children’s Healthcare of Atlanta, 1405 Clifton Road NE, Atlanta, GA 30329 USA
| | - Cara Doughty
- Section of Emergency Medicine, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, 6621 Fannin Street, Suite A210, Houston, TX 77030 USA
| | - Jennifer Arnold
- Department of Pediatrics, Maternal, Fetal, Neonatal Institute, Johns Hopkins All Children’s Hospital, 501 6th Avenue S, St. Petersburg, FL 33701 USA
| | - Kimberly Stone
- Department of Pediatrics, Division of Emergency Medicine, Seattle Children’s Hospital and University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195 USA
| | - Jennifer Reid
- Department of Pediatrics, Division of Emergency Medicine, Seattle Children’s Hospital and University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195 USA
| | - Ashley Dalpiaz
- Department of Pediatrics, Children’s Healthcare of Atlanta, 1655 Tullie Circle, Atlanta, GA 30329 USA
| | - Kiran B. Hebbar
- Department of Pediatrics, Division of Pediatric Critical Care, Children’s Healthcare of Atlanta, 1405 Clifton Road NE, Atlanta, GA 30329 USA
| |
Collapse
|
34
|
Garcia-Ochoa C, Feldman LS, Nguan C, Monroy-Cuadros M, Arnold J, Boudville N, Cuerden M, Dipchand C, Eng M, Gill J, Gourlay W, Karpinski M, Klarenbach S, Knoll G, Lentine KL, Lok CE, Luke P, Prasad GVR, Sener A, Sontrop JM, Storsley L, Treleaven D, Garg AX. Perioperative Complications During Living Donor Nephrectomy: Results From a Multicenter Cohort Study. Can J Kidney Health Dis 2019; 6:2054358119857718. [PMID: 31367455 PMCID: PMC6643179 DOI: 10.1177/2054358119857718] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 04/30/2019] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND While living kidney donation is considered safe in healthy individuals, perioperative complications can occur due to several factors. OBJECTIVE We explored associations between the incidence of perioperative complications and donor characteristics, surgical technique, and surgeon's experience in a large contemporary cohort of living kidney donors. DESIGN Living kidney donors enrolled prospectively in a multicenter cohort study with some data collected retrospectively after enrollment was complete (eg, surgeon characteristics). SETTING Living kidney donor centers in Canada (n = 12) and Australia (n = 5). PATIENTS Living kidney donors who donated between 2004 and 2014 and the surgeons who performed the living kidney donor nephrectomies. MEASUREMENTS Operative and hospital discharge medical notes were collected prospectively, with data on perioperative (intraoperative and postoperative) information abstracted from notes after enrollment was complete. Complications were graded using the Clavien-Dindo system and further classified into minor and major. In 2016, surgeons who performed the nephrectomies were invited to fill an online survey on their training and experience. METHODS Multivariable logistic regression models with generalized estimating equations were used to compare perioperative complication rates between different groups of donors. The effect of surgeon characteristics on the complication rate was explored using a similar approach. Poisson regression was used to test rates of overall perioperative complications between high- and low-volume centers. RESULTS Of the 1421 living kidney donor candidates, 1042 individuals proceeded with donation, where 134 (13% [95% confidence interval (CI): 11%-15%]) experienced 142 perioperative complications (55 intraoperative; 87 postoperative). The most common intraoperative complication was organ injury and the most common postoperative complication was ileus. No donors died in the perioperative period. Most complications were minor (90% of 142 complications [95% CI: 86%-96%]); however, 12 donors (1% of 1042 [95% CI: 1%-2%]) experienced a major complication. No statistically significant differences were observed between donor groups and the rate of complications. A total of 43 of 48 eligible surgeons (90%) completed the online survey. Perioperative complication rates did not vary significantly by surgeon characteristics or by high- versus low-volume centers. LIMITATIONS Operative and discharge reporting is not standardized and varies among surgeons. It is possible that some complications were missed. The online survey for surgeons was completed retrospectively, was based on self-report, and has not been validated. We had adequate statistical power only to detect large effects for factors associated with a higher risk of perioperative complications. CONCLUSIONS This study confirms the safety of living kidney donation as evidenced by the low rate of major perioperative complications. We did not identify any donor or surgeon characteristics associated with a higher risk of perioperative complications. TRIAL REGISTRATIONS NCT00319579: A Prospective Study of Living Kidney Donation (https://clinicaltrials.gov/ct2/show/NCT00319579)NCT00936078: Living Kidney Donor Study (https://clinicaltrials.gov/ct2/show/NCT00936078).
Collapse
Affiliation(s)
- Carlos Garcia-Ochoa
- Division of Nephrology, Department of
Medicine, Western University, London, ON, Canada
| | | | - Christopher Nguan
- Department of Urologic Sciences, The
University of British Columbia, Vancouver, Canada
| | | | - Jennifer Arnold
- Division of Nephrology, Department of
Medicine, Western University, London, ON, Canada
| | - Neil Boudville
- Medical School, The University of
Western Australia, Perth, Australia
| | - Meaghan Cuerden
- Division of Nephrology, Department of
Medicine, Western University, London, ON, Canada
| | - Christine Dipchand
- Division of Nephrology, Department of
Medicine, Dalhousie University, Halifax, NS, Canada
| | - Michael Eng
- Department of Urologic Sciences, The
University of British Columbia, Vancouver, Canada
| | - John Gill
- Division of Nephrology, The University
of British Columbia, Vancouver, Canada
| | - William Gourlay
- Department of Urologic Sciences, The
University of British Columbia, Vancouver, Canada
| | - Martin Karpinski
- Department of Medicine, University of
Manitoba, Winnipeg, Canada
| | | | - Greg Knoll
- Division of Nephrology, Department of
Medicine, Ottawa Hospital Research Institute, ON, Canada
| | - Krista L. Lentine
- Centre for Abdominal Transplantation,
Saint Louis University School of Medicine, MO, USA
| | | | - Patrick Luke
- Department of Urology, Western
University, London, ON, Canada
| | - G. V. Ramesh Prasad
- Division of Nephrology, Department of
Medicine, University of Toronto, ON, Canada
| | - Alp Sener
- Department of Urology, Western
University, London, ON, Canada
| | - Jessica M. Sontrop
- Department of Epidemiology &
Biostatistics, Western University, London, ON, Canada
| | - Leroy Storsley
- Department of Internal Medicine,
University of Manitoba, Winnipeg, Canada
| | - Darin Treleaven
- Division of Nephrology, Department of
Medicine, McMaster University, Hamilton, ON, Canada
| | - Amit X. Garg
- Division of Nephrology, Department of
Medicine, Western University, London, ON, Canada
| | | |
Collapse
|
35
|
Barnieh L, Klarenbach S, Arnold J, Cuerden M, Knoll G, Lok C, Sontrop JM, Miller M, Ramesh Prasad GV, Przech S, Garg AX. Nonreimbursed Costs Incurred by Living Kidney Donors: A Case Study From Ontario, Canada. Transplantation 2019; 103:e164-e171. [PMID: 31246933 DOI: 10.1097/tp.0000000000002685] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Living donors may incur out-of-pocket costs during the donation process. While many jurisdictions have programs to reimburse living kidney donors for expenses, few programs have been evaluated. METHODS The Program for Reimbursing Expenses of Living Organ Donors was launched in the province of Ontario, Canada in 2008 and reimburses travel, parking, accommodation, meals, and loss of income; each category has a limit and the maximum total reimbursement is $5500 CAD. We conducted a case study to compare donors' incurred costs (out-of-pocket and lost income) with amounts reimbursed by Program for Reimbursing Expenses of Living Organ Donors. Donors with complete or partial cost data from a large prospective cohort study were linked to Ontario's reimbursement program to determine the gap between incurred and reimbursed costs (n = 159). RESULTS The mean gap between costs incurred and costs reimbursed to the donors was $1313 CAD for out-of-pocket costs and $1802 CAD for lost income, representing a mean reimbursement gap of $3115 CAD. Nondirected donors had the highest mean loss for out-of-pocket costs ($2691 CAD) and kidney paired donors had the highest mean loss for lost income ($4084 CAD). There were no significant differences in the mean gap across exploratory subgroups. CONCLUSIONS Reimbursement programs minimize some of the financial loss for living kidney donors. Opportunities remain to remove the financial burden of living kidney donors.
Collapse
Affiliation(s)
- Lianne Barnieh
- Department of Clinical Epidemiology and Biostatistics, London Health Sciences Centre, Western University, London, ON, Canada
| | - Scott Klarenbach
- Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - Jennifer Arnold
- Department of Clinical Epidemiology and Biostatistics, London Health Sciences Centre, Western University, London, ON, Canada
| | - Meaghan Cuerden
- Department of Clinical Epidemiology and Biostatistics, London Health Sciences Centre, Western University, London, ON, Canada
| | - Greg Knoll
- Department of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Charmaine Lok
- Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Jessica M Sontrop
- Department of Clinical Epidemiology and Biostatistics, London Health Sciences Centre, Western University, London, ON, Canada
| | - Matthew Miller
- Division of Nephrology and Transplantation, McMaster University, Hamilton, ON, Canada
| | | | - Sebastian Przech
- Department of Clinical Epidemiology and Biostatistics, London Health Sciences Centre, Western University, London, ON, Canada
| | - Amit X Garg
- Department of Clinical Epidemiology and Biostatistics, London Health Sciences Centre, Western University, London, ON, Canada
| |
Collapse
|
36
|
Nguyen CL, Gillies MC, Nguyen V, Daien V, Cohn A, Banerjee G, Arnold J. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti–Vascular Endothelial Growth Factor Agents. Ophthalmology 2019; 126:735-742. [DOI: 10.1016/j.ophtha.2018.11.036] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2018] [Revised: 10/05/2018] [Accepted: 11/30/2018] [Indexed: 11/24/2022] Open
|
37
|
McKeirnan KC, Bertsch TG, Arnold J, Panther SG. Using Team-Based Learning to Train Student Pharmacists to Perform Tuberculin Skin Testing. Am J Pharm Educ 2019; 83:6622. [PMID: 31223147 PMCID: PMC6581343 DOI: 10.5688/ajpe6622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Accepted: 08/22/2017] [Indexed: 06/09/2023]
Abstract
Objective. To evaluate the effectiveness of a team-based learning (TBL) model in training students to properly administer and interpret a tuberculin skin test (TST) in a laboratory course. Method. Team-based learning was used to deliver TST training to all second-year student pharmacists (n=120) in a patient care laboratory course. A 10-item TST Learning Opinion Survey was developed and administered to assess student pharmacists' self-perceived achievement of the class learning objectives, opinions about TBL learning experience, and interest in making TST a part of future practice. Results. All 120 student pharmacists achieved competency standards during skills evaluation. One hundred thirteen out of 120 students completed the survey instrument. The majority of respondents either agreed or strongly agreed that TBL helped them meet the TST training learning objectives of: demonstrating administration proficiency; demonstrating interpretation competency; proper reporting and patient counseling with a positive test result; and identifying when a second TST was necessary. Additionally, a majority of respondents agreed or strongly agreed that the TBL model improved their knowledge of pre-laboratory material, aided their confidence in practicing TST placement, and improved their communication skills through peer work in a TBL environment. Conclusion. Through this innovative model, student pharmacists met the TST learning objectives and developed knowledge and confidence. This activity can be replicated at other colleges, expanding the development of student pharmacists who are confident in their ability to provide TST services.
Collapse
Affiliation(s)
| | - Taylor G Bertsch
- Washington State University College of Pharmacy, Spokane, Washington
| | - Jennifer Arnold
- Washington State University College of Pharmacy, Spokane, Washington
| | - Shannon G Panther
- Washington State University College of Pharmacy, Spokane, Washington
| |
Collapse
|
38
|
Summers S, Leigh L, Arnold J. Personnel Shortage and Caseload Management of Students with Visual Impairments: Children at Risk. Journal of Visual Impairment & Blindness 2019. [DOI: 10.1177/0145482x0610001007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Ghoneim N, Dariya V, Guffey D, Minard CG, Frugé E, Harris LL, Johnson KE, Arnold J. Teaching NICU Fellows How to Relay Difficult News Using a Simulation-Based Curriculum: Does Comfort Lead to Competence? Teach Learn Med 2019; 31:207-221. [PMID: 30428732 DOI: 10.1080/10401334.2018.1490649] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
PROBLEM Neonatal Intensive Care Unit (NICU) clinicians must frequently relay difficult news to patient families, and the need for formal training for NICU trainees to develop this skill has been established. Although previous studies have shown improved trainee self-efficacy and comfort in handling difficult conversations after formal communication training, it remains unclear whether these interventions lead to improved objectively assessed short-term and long-term performance. INTERVENTION A simulation-based intervention emphasizing the SPIKES protocol for delivery of bad news was implemented for 15 fellows in the 3-year Baylor College of Medicine Neonatal-Perinatal Medicine fellowship program in the 2013-2014 academic year. Simulations involved video-recorded encounters between each fellow and a standardized parent (SP) involving communication of difficult news. Each fellow was evaluated before (preintervention), immediately after (postintervention), and 3-4 months after the intervention (follow-up) with an (a) evaluation of video-recorded sessions by two expert raters blinded to the timing of the encounter (blinded rater evaluation [BRE]), (b) Self-Assessment Questionnaire, (c) Content Test evaluating knowledge of taught concepts, and (d) SP evaluation (SPE). CONTEXT The 1st- and 2nd/3rd-year fellows participated in the study at separate times in the academic year to accommodate their schedules. First-year fellows had had more prior communication training and less NICU clinical experience than the 2nd/3rd-year fellows at the time of their intervention. OUTCOME Although all fellows displayed improved Self-Assessment and Content Test scores at postintervention with retention at the follow-up assessment, the BREs showed no statistically significant improvement in postintervention scores and showed a decline in follow-up scores. First-year fellows had higher BRE postintervention scores than the senior fellows. SPEs showed no difference in scores at all 3 assessment stages. LESSONS LEARNED As previously described in the literature, trainee self-efficacy and knowledge may improve in the short term and long term with a simulation-based curriculum in communication of difficult news. However, these results may be inconsistent with those of objective evaluations by expert raters and standardized parents. The impact of the curriculum may be heightened if it reinforces previously learned skills, but the effect may wane over time if not reinforced frequently with additional formal training or in the clinical setting. The results of this study highlight the importance of objective assessments in evaluating the utility of a simulation-based communication curriculum and the need for longitudinal curricula to promote retention of the concepts and skills being taught.
Collapse
Affiliation(s)
- Nada Ghoneim
- a Department of Pediatrics , Baylor College of Medicine , Houston , Texas , USA
| | - Vedanta Dariya
- a Department of Pediatrics , Baylor College of Medicine , Houston , Texas , USA
| | - Danielle Guffey
- b Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine , Houston , Texas , USA
| | - Charles G Minard
- b Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine , Houston , Texas , USA
| | - Ernest Frugé
- a Department of Pediatrics , Baylor College of Medicine , Houston , Texas , USA
| | - Leslie L Harris
- a Department of Pediatrics , Baylor College of Medicine , Houston , Texas , USA
| | - Karen E Johnson
- a Department of Pediatrics , Baylor College of Medicine , Houston , Texas , USA
| | - Jennifer Arnold
- a Department of Pediatrics , Baylor College of Medicine , Houston , Texas , USA
| |
Collapse
|
40
|
Korobelnik JF, Lu C, Katz TA, Dhoot DS, Loewenstein A, Arnold J, Staurenghi G. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies. Ophthalmol Retina 2019; 3:663-669. [PMID: 31103642 DOI: 10.1016/j.oret.2019.03.015] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 03/08/2019] [Accepted: 03/19/2019] [Indexed: 11/28/2022]
Abstract
PURPOSE To evaluate the effect of baseline subretinal fluid (SRF) on treatment outcomes with intravitreal aflibercept injection (IAI) versus laser treatment in patients with diabetic macular edema (DME) in the VIVID and VISTA studies. DESIGN Post hoc analysis of 2 randomized controlled trials. PARTICIPANTS Eight hundred seventy-two patients with DME. METHODS We randomized patients to receive IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or laser. MAIN OUTCOME MEASURES Effect of presence or absence of baseline SRF on visual outcomes in the integrated dataset at weeks 52 and 100. RESULTS Mean best-corrected visual acuity (BCVA) gains in the 2q4, 2q8, and laser arms at week 52 were +14.5, +11.0, and -2.3 letters, respectively, (those with baseline SRF) and +10.3, +10.6, and +2.5 letters, respectively, (those without). At week 100, mean gains were +13.5, +10.9, and -2.3 letters (those with baseline SRF) and +10.6, +10.0, and +2.7 letters (those without). The treatment effect for IAI versus laser from baseline to week 52 of 100 was greater for patients with baseline SRF versus those without (nominal P < 0.001, for interaction). The proportions of patients who gained 15 letters or more in the 2q4, 2q8, and laser arms at week 52 were 52.3%, 40.2%, and 8.9%, respectively, (those with baseline SRF) and 30.9%, 29.1%, and 8.2%, respectively, (those without) and at week 100 were 50.0%, 35.4%, and 12.9%, respectively, (those with baseline SRF) and 33.3%, 30.5%, and 12.5%, respectively, (those without). Time to first sustained SRF clearance seemed to be shorter in the IAI arms versus laser. The overall safety profile was similar in the IAI arms. CONCLUSIONS This post hoc analysis demonstrated the visual outcome benefits of IAI over laser, regardless of baseline SRF status. A greater treatment effect of IAI was observed in patients with baseline SRF versus those without; however, no meaningful impact of baseline SRF status on treatment outcomes with IAI was demonstrated, indicating that the differential effects of laser might have been the driving force behind the different treatment outcomes in both groups.
Collapse
Affiliation(s)
- Jean-Francois Korobelnik
- Service d'Ophtalmologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Team LEHA, Bordeaux Population Health Research Center, Inserm, University of Bordeaux, Bordeaux, France.
| | | | | | - Dilsher S Dhoot
- California Retina Consultants and Research Foundation, Santa Barbara, California
| | - Anat Loewenstein
- Department of Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel
| | | | - Giovanni Staurenghi
- Eye Clinic, Department of Biomedical and Clinical Science, Luigi Sacco Hospital, University of Milan, Milan, Italy
| |
Collapse
|
41
|
Radville L, Aldous A, Arnold J, Hall AK. Outcomes from an elective medical student Research Scholarly Concentration program. J Investig Med 2019; 67:1018-1023. [PMID: 30723119 DOI: 10.1136/jim-2018-000943] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/12/2019] [Indexed: 02/01/2023]
Abstract
To examine how to increase research career outcomes among medical graduates, we analyzed the impact of the Research Scholarly Concentration at The George Washington University School of Medicine and Health Sciences. Residency placement, subsequent scholarship, and career outcomes were compared among 670 graduates who participated in the elective Clinical and Translational Research Scholarly Concentration or no Concentration between 2009 and 2018. We conducted a retrospective study of residency match (highly selective vs less selective), job type (academic vs non-academic), and postmedical school publications (any vs none). We compared the outcomes between Research Scholarly Concentration graduates and those with no Concentration, matched by graduation year (n=335). For Research Scholarly Concentration graduates, we examined the association between research outcomes and duration of research experience before medical school (n=232). Research Scholarly Concentration graduates were more likely to place in a highly selective residency (40.2% vs 21.6%, p<0.0001), 68% more likely to publish after medical school (OR=1.68, 95% CI 1.10 to 2.58), and almost four times as likely to have taken an academic health center job (OR=3.82, 95% CI 1.72 to 8.46) than graduates with no Concentration. Surprisingly, the length of research experience before medical school was not associated with these outcomes among Research Scholarly Concentration graduates. This suggests that a medical school Research Scholarly Concentration is effective in training physician researchers and should be available to both novices and research-experienced matriculants. These data suggest how other medical schools might plan Scholarly Concentration programs to improve research outcomes among medical graduates.
Collapse
Affiliation(s)
- Laura Radville
- School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, USA
| | - Annette Aldous
- Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA
| | - Jennifer Arnold
- School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, USA
| | - Alison K Hall
- School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, USA
| |
Collapse
|
42
|
Barnieh L, Kanellis J, McDonald S, Arnold J, Sontrop JM, Cuerden M, Klarenbach S, Garg AX, Boudville N. Direct and indirect costs incurred by Australian living kidney donors. Nephrology (Carlton) 2018; 23:1145-1151. [DOI: 10.1111/nep.13205] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/03/2017] [Indexed: 12/22/2022]
Affiliation(s)
- Lianne Barnieh
- Division of Nephrology; Western University; London Ontario Canada
| | - John Kanellis
- Department of Nephrology, Monash Health and Centre for Inflammatory Diseases, Department of Medicine; Monash University; Melbourne Victoria Australia
| | - Stephen McDonald
- Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital; Adelaide South Australia Australia
| | - Jennifer Arnold
- Division of Nephrology; Western University; London Ontario Canada
| | - Jessica M. Sontrop
- Department of Epidemiology and Biostatistics; Western University; London Ontario Canada
| | - Meaghan Cuerden
- Division of Nephrology; Western University; London Ontario Canada
| | | | - Amit X. Garg
- Division of Nephrology; Western University; London Ontario Canada
- Department of Epidemiology and Biostatistics; Western University; London Ontario Canada
| | - Neil Boudville
- Medical School, Faculty of Medicine, Dentistry and Health Sciences; University of Western; Crawley Western Australia Australia
| | | |
Collapse
|
43
|
Affiliation(s)
- Jennifer Arnold
- Medical Director, Center for Simulation and Innovative Education, Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.
| | - Alexandra Luton
- Clinical and Education Consultant, Houston, TX, United States
| | - Jonathan Davies
- Department of Pediatrics, Section of Neonatology, Baylor College of Medicine, Houston, TX, United States
| |
Collapse
|
44
|
Opzoomer J, Caron J, Muliaditan T, Okesola M, Kordasti S, Spicer J, Arnold J. PO-322 Investigating co-expression of the immune checkpoints heme oxygenase-1 and PD-L in breast cancer. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
45
|
Caranica C, Al-Omari A, Deng Z, Griffith J, Nilsen R, Mao L, Arnold J, Schüttler HB. Ensemble methods for stochastic networks with special reference to the biological clock of Neurospora crassa. PLoS One 2018; 13:e0196435. [PMID: 29768444 PMCID: PMC5955539 DOI: 10.1371/journal.pone.0196435] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Accepted: 04/12/2018] [Indexed: 11/18/2022] Open
Abstract
A major challenge in systems biology is to infer the parameters of regulatory networks that operate in a noisy environment, such as in a single cell. In a stochastic regime it is hard to distinguish noise from the real signal and to infer the noise contribution to the dynamical behavior. When the genetic network displays oscillatory dynamics, it is even harder to infer the parameters that produce the oscillations. To address this issue we introduce a new estimation method built on a combination of stochastic simulations, mass action kinetics and ensemble network simulations in which we match the average periodogram and phase of the model to that of the data. The method is relatively fast (compared to Metropolis-Hastings Monte Carlo Methods), easy to parallelize, applicable to large oscillatory networks and large (~2000 cells) single cell expression data sets, and it quantifies the noise impact on the observed dynamics. Standard errors of estimated rate coefficients are typically two orders of magnitude smaller than the mean from single cell experiments with on the order of ~1000 cells. We also provide a method to assess the goodness of fit of the stochastic network using the Hilbert phase of single cells. An analysis of phase departures from the null model with no communication between cells is consistent with a hypothesis of Stochastic Resonance describing single cell oscillators. Stochastic Resonance provides a physical mechanism whereby intracellular noise plays a positive role in establishing oscillatory behavior, but may require model parameters, such as rate coefficients, that differ substantially from those extracted at the macroscopic level from measurements on populations of millions of communicating, synchronized cells.
Collapse
Affiliation(s)
- C. Caranica
- Department of Statistics, University of Georgia, Athens, Georgia
| | - A. Al-Omari
- Department of Biomedical Systems and Informatics Engineering, Yarmouk University, Irbid, Jordan
| | - Z. Deng
- School of Electrical and Computer Engineering, College of Engineering, University of Georgia, Athens, Georgia
| | - J. Griffith
- Genetics Department, University of Georgia, Athens, Georgia
- College of Agricultural and Environmental Sciences, University of Georgia, Athens, Georgia
| | - R. Nilsen
- Genetics Department, University of Georgia, Athens, Georgia
| | - L. Mao
- School of Electrical and Computer Engineering, College of Engineering, University of Georgia, Athens, Georgia
| | - J. Arnold
- Genetics Department, University of Georgia, Athens, Georgia
- * E-mail:
| | - H.-B. Schüttler
- Department of Physics and Astronomy, University of Georgia, Athens, Georgia
| |
Collapse
|
46
|
Parker BF, Hohloch S, Pankhurst JR, Zhang Z, Love JB, Arnold J, Rao L. Interactions of vanadium(iv) with amidoxime ligands: redox reactivity. Dalton Trans 2018; 47:5695-5702. [PMID: 29632905 DOI: 10.1039/c7dt04069e] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The use of amidoxime-functionalized polymer fibers as a sorbent for uranium has attracted recent interest for the extraction of uranium from seawater. Vanadium is one of the main competing ions for uranium sorption as V(v) species, however, vanadium is also present as V(iv) in seawater. In the present study, the interactions of V(iv) with amidoxime and similar ligands were explored. Attempts were made to synthesize V(iv) complexes of glutaroimide-dioxime, a molecular analogue of polymer sorbents. However, V(iv) was found to react irreversibly with glutaroimide-dioxime and other oxime groups, oxidizing to the V(v) oxidation state. We have explored the reactions and propose mechanisms, as well as characterized the redox behavior of the vanadium-glutaroimide-dioxime complex.
Collapse
Affiliation(s)
- B F Parker
- Department of Chemistry, University of California - Berkeley, Berkeley, CA 94720, USA.
| | | | | | | | | | | | | |
Collapse
|
47
|
Habbous S, Arnold J, Begen MA, Boudville N, Cooper M, Dipchand C, Dixon SN, Feldman LS, Goździk D, Karpinski M, Klarenbach S, Knoll GA, Lam NN, Lentine KL, Lok C, McArthur E, McKenzie S, Miller M, Monroy-Cuadros M, Nguan C, Prasad GVR, Przech S, Sarma S, Segev DL, Storsley L, Garg AX. Duration of Living Kidney Transplant Donor Evaluations: Findings From 2 Multicenter Cohort Studies. Am J Kidney Dis 2018; 72:483-498. [PMID: 29580662 DOI: 10.1053/j.ajkd.2018.01.036] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 01/11/2018] [Indexed: 01/14/2023]
Abstract
BACKGROUND A prolonged living kidney donor evaluation may result in worse outcomes for transplant recipients. Better knowledge of the duration of this process may help inform future donors and identify opportunities for improvement. STUDY DESIGN 1 prospective and 1 retrospective cohort study. SETTING & PARTICIPANTS At 16 Canadian and Australian transplantation centers (prospective cohort) and 5 Ontario transplantation centers (retrospective cohort), we assessed the duration of living kidney donor evaluation and explored donor, recipient, and transplantation factors associated with longer evaluation times. Data were obtained from 2 sources: donor medical records using chart abstraction and health care administrative databases. PREDICTORS Donor and recipient demographics, direct versus paired donation, center-level variables. OUTCOMES Duration of living donor evaluation. RESULTS The median total duration of transplantation evaluation (time from when the candidate started the evaluation until donation) was 10.3 (IQR, 6.5-16.7) months. The median duration from evaluation start until approval to donate was 7.9 (IQR, 4.6-14.1) months, and from approval until donation was 0.7 (IQR, 0.3-2.4) months, respectively. The median time between the first and last consultation among donors who completed a nephrology, surgery, and psychosocial assessment in the prospective cohort was 3.0 (IQR, 1.0-6.3) months, and between computed tomography angiography and donation was 4.8 (IQR, 2.6-9.2) months. After adjustment, the total duration of transplantation evaluation was longer if the donor participated in paired donation (6.6 [95% CI, 1.6-9.7] months) and if the recipient was referred later relative to the donor's evaluation start date (0.9 [95% CI, 0.8-1.0] months [per month of delayed referral]). Results depended on whether the recipient was receiving dialysis. LIMITATIONS Living donor candidates who did not donate were not included and proxy measures were used for some dates in the donor evaluation process. CONCLUSIONS The duration of kidney transplant donor evaluation is variable and can be lengthy. Better understanding of the reasons for a prolonged evaluation may inform quality improvement initiatives to reduce unnecessary delays.
Collapse
Affiliation(s)
- Steven Habbous
- Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada
| | | | - Mehmet A Begen
- Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada; Ivey School of Business, Western University, London, Ontario, Canada
| | - Neil Boudville
- University of Western Australia, Nedlands, WA, Australia
| | | | | | - Stephanie N Dixon
- Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada; Institute for Clinical Evaluative Sciences, Ontario, Canada
| | | | | | | | | | - Greg A Knoll
- Ottawa General Hospital, Ottawa, Ontario, Canada
| | - Ngan N Lam
- University of Alberta, Edmonton, Alberta, Canada
| | - Krista L Lentine
- Centre for Abdominal Transplantation, St. Louis University School of Medicine, St. Louis, MO
| | | | - Eric McArthur
- McGill University Health Centre, Montreal, Quebec, Canada
| | | | | | | | - Chris Nguan
- Vancouver General Hospital, Vancouver, British Columbia, Canada
| | | | - Sebastian Przech
- Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada
| | - Sisira Sarma
- Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada
| | - Dorry L Segev
- Division of Transplantation, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD
| | - Leroy Storsley
- Winnipeg Health Sciences Centre, Winnipeg, Manitoba, Canada
| | - Amit X Garg
- Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada; London Health Sciences Centre, London, Ontario, Canada; Institute for Clinical Evaluative Sciences, Ontario, Canada.
| | | |
Collapse
|
48
|
Abstract
This review provides a brief background on the extraction of uranium from seawater as well as recent work by the United States Department of Energy on this project. The world's oceans contain uranium at 3 parts per billion, and despite this low concentration, there has been historical interest in harvesting it, mainly in Japan in the 1980s and the United States in this decade. Improvements in materials, chemistry, and deployment methods have all been made, with the ultimate goal of lower cost. This has been partially realized, dropping from approximately $2000 per kg U3O8 extracted in 1984 to $500 per kg today, although this is not yet competitive with terrestrial uranium. This technology may become cost-competitive if the cost of land-based uranium rises, especially if seawater extraction technology is improved further. The coordination chemistry aspects of the project are described in more detail, exploring the functional groups that are present on typical polymer sorbents as well as small-molecule analogues of these ligands. Selectivity for uranium over other metals, particularly vanadium, remains problematic, and techniques to both quantify binding strength and selectivity in order to overcome this issue are essential for future cost improvements.
Collapse
Affiliation(s)
- B F Parker
- Department of Chemistry, University of California - Berkeley, Berkeley, CA 94720, USA.
| | | | | | | |
Collapse
|
49
|
Arnold J, Gustin MS, Weisberg PJ. Evidence for Nonstomatal Uptake of Hg by Aspen and Translocation of Hg from Foliage to Tree Rings in Austrian Pine. Environ Sci Technol 2018; 52:1174-1182. [PMID: 29232509 DOI: 10.1021/acs.est.7b04468] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
To determine whether trees are reliable biomonitors of air mercury (Hg) pollution concentrations were measured in bark, foliage, and tree rings. Data were developed using 4-year old Pinus and Populus trees grown from common genetic stock in Oregon and subsequently transferred to four air treatments differing in gaseous oxidized mercury (GOM) chemistry and total gaseous Hg (TGM) concentrations. Soil of a subset of trees was spiked with HgBr2 in solution to test for root uptake. Results indicate no significant effect of the soil spike or GOM compounds on tree tissue Hg concentrations. TGM treatment had a significant effect on Pinus and Populus foliage, and Pinus year 5 growth ring concentrations. Populus foliar Hg concentrations were highest in the exposure where 24 h TGM concentrations were highest, indicating the importance of the nonstomatal pathway for uptake. Pinus tree ring concentrations were correlated to day time TGM concentrations suggesting Hg accumulation into tree rings is by way of the stomata and subsequent translocation by way of phloem. Populus leaves and Pinus rings can be used as biomonitors for TGM concentrations over space. However, the use of trees as temporal proxies requires further investigation due to radial translocation observed in active sapwood tree rings.
Collapse
Affiliation(s)
- Jennifer Arnold
- Department of Natural Resources and Environmental Science University of Nevada-Reno Reno, Nevada 89557, United States
| | - Mae Sexauer Gustin
- Department of Natural Resources and Environmental Science University of Nevada-Reno Reno, Nevada 89557, United States
| | - Peter J Weisberg
- Department of Natural Resources and Environmental Science University of Nevada-Reno Reno, Nevada 89557, United States
| |
Collapse
|
50
|
Abstract
Homoleptic U(iv) and U(iii) amidate complexes have been isolated and characterized; these species undergo an unusual and reversible change in coordination number upon reduction/oxidation.
Collapse
Affiliation(s)
- M. D. Straub
- Department of Chemistry
- University of California
- Berkeley
- USA
- Chemical Sciences Division
| | - S. Hohloch
- Department of Chemistry
- University of California
- Berkeley
- USA
- Chemical Sciences Division
| | - S. G. Minasian
- Chemical Sciences Division
- Lawrence Berkeley National Laboratory
- Berkeley
- USA
| | - J. Arnold
- Department of Chemistry
- University of California
- Berkeley
- USA
- Chemical Sciences Division
| |
Collapse
|